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Abstract
The emergence of tandem mass spectrometry (MS/MS) technology has signifi-
cantly accelerated protein identification and quantification in proteomics. It enables
high-throughput analysis of proteins and their quantities in a complex protein mix-
ture. A mass spectrometer can easily and rapidly generate large volumes of mass
spectral data for a biological sample. This bulk of data makes manual interpretation
impossible and has also brought numerous challenges in automated data analysis. Al-
gorithmic solutions have been proposed and provide indispensable analytical support
in current proteomic experiments. However, new algorithms are still needed to ei-
ther improve result accuracy or provide additional data analysis capabilities for both
protein identification and quantification.
Accurate identification of proteins in a sample is the preliminary requirement
of a proteomic study. In many cases, a mass spectrum cannot provide complete
information to identify the peptide without ambiguity because of the inefficiency of
the peptide fragmentation technique and the prevalent existence of noise. We propose
ADEPTS to this problem using the complementary information provided in different
types of mass spectra. Meanwhile, the occurrence of posttranslational modifications
(PTMs) on proteins is another major issue that prevents the interpretation of a
large portion of spectra. Using current software tools, users have to specify possible
PTMs in advance. However, the number of possible PTMs has to be limited since
specifying more PTMs to the software leads to a longer running time and lower result
accuracy. Thus, we develop DeNovoPTM and PeaksPTM to provide efficient and
accurate solutions.
Glycosylation is one of the most frequently observed PTMs in proteomics. It plays
important roles in many disease processes and thus has attracted growing research in-
terest. However, lack of algorithms that can identify intact glycopeptides has become
the major obstacle that hinders glycoprotein studies. We propose a novel algorithm,
GlycoMaster DB, to fulfil this urgent requirement.
Additional research is presented on protein quantification, which studies the changes
of protein quantity by comparing two or more mass spectral datasets. A crucial prob-
lem in the quantification is to correct the retention time distortions between different
datasets. Heuristic solutions from previous research have been used in practice but
none of them has yet claimed a clear optimization goal. To address this issue, we
propose a combinatorial model and practical algorithms for this problem.
v
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Chapter 1
Introduction
1.1 Background
Proteomics refers to the comprehensive study of the entire protein content in a spe-
cific cell, tissue or organism, or body fluids, ie. blood and urine. Its goal is to obtain
a global and integrated view of disease processes, cellular processes and networks at
the protein level [18]. Qualitative and quantitative proteomic analysis can help in
discovering unique biomarkers, which play extremely important roles in the diagnos-
tic and therapeutic procedures of some diseases, such as cancer, in modern medical
research [119].
Currently, tandem mass spectrometry (MS/MS) is the standard analytical tech-
nology in proteomics. It enables high-throughput analysis on proteins and their quan-
tities in a complex protein mixture with high sensitivity, selectivity and accuracy [36].
A tandem mass spectrometer can easily and rapidly generate large volumes of spec-
tral data for a biological sample. It makes manual interpretation become unfeasible
and has also brought numerous challenges in automated data analysis. Elegant algo-
rithmic solutions have been proposed and provide indispensable analytical support in
current proteomic experiments.
Accurate identification of proteins is the preliminary requirement in proteomics.
Protein sequence databases have been constructed by gathering proteins either se-
quenced in previous experiments or predicted from genes. MS/MS data can then
be interpreted by searching these protein databases [163, 164]. In contrast, de novo
sequencing approaches have also been developed to study un-sequenced organisms or
1
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species, of which the proteins are directly identified from spectral data without the
assistance of protein databases [34].
Inaccurate identification is the major obstacle that hinders de novo sequencing
to be a reliable approach for protein identification [111]. Recently, instruments that
integrate multiple fragmentation modules have been developed. Two or more frag-
mentation methods are used to generate different types of spectra from the same
sample, such as collision-induced dissociation (CID), higher energy collisional dis-
sociation (HCD), and electron-transfer dissociation (ETD). It becomes possible to
improve the de novo sequencing by using multiple types of spectral data.
The occurrence of posttranslational modifications (PTMs) on proteins is of critical
importance to protein functions [159]. Most existing software tools, using either
database search or de novo sequencing approaches, have difficulties handling a large
number of PTMs specified by users. Either the accuracy of the result or the speed
of the algorithms, or both, can be seriously influenced when too many PTMs are
considered [27].
N -linked glycosylation is one of the most frequently observed PTMs in mam-
malian organisms. The identification of glycopeptides and glycans is crucial to studies
of cellular processes, particularly some disease processes [19]. Compared to peptides
with other types of PTMs, intact N -linked glycopeptides generate spectral data with
explicitly different patterns. The analysis of such data heavily depends on manual in-
terpretation and no automated solution is currently available for a large scale analysis.
This has become the major obstacle to the progress of glycoproteomics [33].
Protein quantification provides the information of protein quantity changes and
assists in discovering important biomarkers of particular diseases. The label-free
quantification method is one of the two commonly used approaches in protein quan-
tification [11]. It has attracted growing interest since no additional chemistry or sam-
ple preparation steps are required. However, the convenience in experiments leads
to more computational challenges, which demands efficient and accurate algorithmic
solutions.
1.2 Contributions
This dissertation is mainly to propose algorithmic solutions for protein identification
and PTM characterization. The following five components constitute the contribu-
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tions of the dissertation:
De novo sequencing using CID/ETD spectrum-pairs: The errors of de
novo sequencing mainly come from ambiguities introduced by missing peaks. In
a spectrum, incomplete information makes it difficult to discriminate amino acid
combinations that share the same mass. However, in a spectrum-pair consisting of
a CID spectrum and an ETD spectrum, the missing peaks in one spectrum may be
present in the other. This fact helps to determine the true amino acid combination and
thus improve the accuracy of de novo sequencing. We propose a de novo sequencing
approach using CID/ETD spectrum-pairs, named ADEPTS. The comparison with
other de novo sequencing software tools shows the better performance of ADEPTS.
De Novo sequencing with many PTMs: Since it is difficult for a researcher
to know all the PTM types in a sample, a natural practice is to consider as many
PTM types as possible and let the data analysis algorithm determine which PTMs
really exist. However, the accuracy of de novo sequencing is significantly degraded
due to the larger search space introduced by considering many PTM types. We
propose DeNovoPTM as a specialized application of de novo sequencing when many
PTM types are considered. Our observation shows that most peptides in a proteomic
study contain only a small number of PTMs per peptide, yet the types of PTMs can
come from a large number of choices. Therefore, it is desirable to include a large
number of PTM types in a de novo sequencing algorithm but limit the number of
PTM occurrences in each peptide to increase the accuracy. A dynamic programming
algorithm for solving this problem is proposed and implemented for practical use.
Searching modified peptides without specifying PTMs: Identification of
modified peptides using conventional database search software tools requires users to
provide a few PTM candidates in advance. However, the complete knowledge of pos-
sibly existing PTMs in a protein mixture cannot be obtained before the analysis. On
the other hand, the efficiency and accuracy reduces significantly when a large number
of PTMs are specified. We present an improved database search tool for modified
peptide identification without pre-specifying PTM candidates. The improvements in
the software include (1) a default setting whereby the software considers all PTMs
included in the Unimod database as variable PTMs, and (2) several search strategies
that significantly reduce the search space. Furthermore, our approach uses the co-
existence of modified and base forms of the same peptide and the rareness of PTMs
to provide powerful discrimination between spurious and real modified peptides. This
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software outperforms several state-of-the-art software packages evaluated in this re-
search.
Characterizing intact glycopeptides: Identification of glycopeptides and gly-
cans is essential to better understand the functions and bioactivities of glycoproteins.
The progress of this study is mainly hindered by the lack of algorithms for intact gly-
copeptide characterization. GlycoMaster DB is proposed to fulfil this urgent require-
ment on N -linked glycopeptides. It is able to analyze the MS/MS data obtained from
a biological sample with glycoproteins being either enriched or not, and from either
HCD/ETD or HCD-only fragmentation. It simultaneously identifies glycopeptide se-
quences and N -linked glycan composition from a user-specified protein database and
a pre-configured N -linked glycan database, respectively. Furthermore, the connec-
tions between glycopeptides and glycans are also reported by GlycoMaster DB. This
connection information makes it possible to determine the glycoprotein identity and
study different forms of a glycoprotein (glycoforms).
Matching peptide features: Protein quantification is to study the abundance
variance of interested proteins from two or more samples. For each of the proteins,
its abundance ratio can be obtained by calculating the ratios of its peptides. In many
cases peptides are not identified in advance and peptide features (signals that are
possibly caused by peptides) are usually used to represent peptides. Thus, pairing
two peptides from different samples means pairing two peptide features from different
feature sets. Mass and retention time are two most important pieces of information
of a peptide feature. The mass is fairly accurate, but the retention time is subject to
some systematic as well as random errors. Features with the same or similar mass are
matched and a matching weight according to the retention time shift is calculated.
The maximum peptide feature matching problem is to compute a match between two
feature sets with the maximum weight. The difficulty of this problem is finding an
“alignment” that maps the retention time from one peptide feature set to the other.
We formulate this problem into a combinatorial model and prove its NP-hardness.
Practical algorithms are provided and compared with other existing methods.
1.3 Overview of Dissertation
The rest of the dissertation is organized as follows:
Chapter 2 introduces the fundamentals of MS/MS-based computational proteomics.
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Both experimental and computational strategies are introduced for better understand-
ing of the subsequent research topics.
Chapter 3 presents ADEPTS, a de novo sequencing approach that improves the
accuracy by using CID/ETD spectrum-pairs.
Chapter 4 presents DeNovoPTM, a de novo sequencing algorithm that improves
the accuracy when many PTMs are considered.
Chapter 5 proposes PeaksPTM, an improved database search approach for efficient
identification of modified peptides, with the consideration of all PTMs in the Unimod
database.
Chapter 6 presents GlycoMaster DB, a database search software tool for the
characterization of intact N -linked glycopeptides from spectral data obtained by
HCD/ETD or HCD-only fragmentation.
Chapter 7 studies the peptide feature matching problem encountered in label-free
protein quantification. The problem is formulated into a combinatorial model and
proven to be NP-hard. Two practical algorithms are provided.
Finally, the summary of this dissertation and future work are presented in Chapter
8.
1.4 Publication Notes
The studies presented in Chapter 3, 4, 5, and 7 have been published as four referred
research articles [64, 63, 60, 89]. The work in Chapter 6 has been submitted for
possible publication.
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Chapter 2
Fundamentals
2.1 Mass Spectrometry
Mass spectrometry (MS) is an analytical technique that measures the mass-to-charge
ratios (m/z) of charged particles. It has been used for both qualitative and quantita-
tive analysis, which includes identifying the composition and structures of unknown
compounds and measuring the quantities of interested molecules. Currently, MS is
widely used in analytical laboratories where physical, chemical, or biological proper-
ties of a great variety of compounds are studied [168].
A mass spectrometer typically consists of three components: an ionizer, a mass
analyzer, and a detector. Molecules are first converted to ions in the ionizer, then
the ions are separated according to their different m/z in the mass analyzer. The
separated ions are then detected by the detector to form a mass spectrum, which
consists of a list of peaks. Each peak is represented by its m/z and intensity. Fig-
ure 2.1 illustrates an example of a mass spectrum. Ions with the same m/z form a
peak and the intensity of a peak indicates the number of such ions detected by the
detector. The isotopes of elements in a molecule also produce isotopic peaks, from
which the charge state of the ion can be determined. The intensity of a peak is related
to the abundance of the corresponding ion. However, the abundance ratio between
two molecules cannot be simply regarded as the intensity ratio of their corresponding
peaks [96]. This is due to the differences in ionization efficiency and detectability of
different molecules, as well as the imperfect reproducibility of MS experiments.
The ionizer and the mass analyzer of a mass spectrometer are implemented with
7
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Figure 2.1: An example of a visualized mass spectrum. The inset illustrates isotopic
peaks with monoisotopic m/z 1396.14. The charge state of the ion can be determined
as two from the m/z difference between two adjacent isotopic peaks.
multiple techniques, causing different properties of the resultant spectral data. Two
types of ionizers are commonly used in proteomics: matrix-assisted laser desorption/
ionization (MALDI) [66] and electrospray ionization (ESI) [102]. MALDI mostly pro-
duces singly charged ions, and ESI can produce multiply charged ions. The advantage
of ESI is that a large molecule can still be detected since its multiply charged ions can
fall into the m/z range of a mass spectrometer. However, the existence of multiply
charged ions increases the complexity of the spectrum and more computational efforts
are required for the spectrum interpretation.
Five types of mass analyzers are commonly used in proteomics: quadrupole, ion
trap (quadrupole ion trap, QIT; linear ion trap, LIT or LTQ), time-of-flight (TOF),
Fourier transform ion cyclotron resonance (FTICR), and Orbitrap. Each type has
different capabilities in terms of sensitivity, accuracy, resolution, m/z range, and other
characteristics [68]. Mass resolution and accuracy are two important parameters to
measure the performance of a mass analyzer. The mass resolution measures the
ability to distinguish two peaks of slightly different m/z. The mass accuracy is the
ratio between the m/z measurement error and the true m/z, and usually measured in
ppm (parts per million). The performance of each mass analyzer is listed in Table 2.1.
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Table 2.1: Comparison of typical performance characteristics of commonly used mass
analyzers in proteomics [12].
Mass analyzer Resolution Accuracy (ppm) m/z range Scan rate
Quadrapole 1,000 100-1,000 50-2,000; 200-4,000 Moderate
QIT 1,000 100-1,000 10-4,000 Moderate
LTQ 2,000 100-500 50-2,000; 200-4,000 Fast
TOF 10,000-20,000 10-100 No upper limit Fast
FTICR 100,000-750,000 <2 50-2000; 200-4,000 Slow
Orbitrap 30,000-100,000 2-5 50-2,000; 200-4,000 Moderate
2.2 Shotgun Proteomics
An explicit goal of proteomics is to characterize all the proteins expressed in a cell or
tissue [4]. The improvements in mass spectrometry instruments, protein and peptide
separation techniques, and the availability of protein sequence databases for many
species has facilitated the analysis of complex protein mixtures using shotgun pro-
teomics. The major steps of shotgun proteomics include the protein digestion by
single or multiple enzymes, the peptide separation by liquid chromatography (LC),
and the peptide analysis using tandem mass spectrometry technology. Peptides are
identified from the spectral data, and proteins can then be determined by matching
these identified peptides to known protein sequences or assembling them into novel
proteins [2, 105]. Shotgun proteomics is currently the dominant analytical approach
in proteomics research [168].
2.3 Tandem Mass Spectrometry
Tandem mass spectrometry (MS/MS) technology involves multiple mass spectrometer
stages and aims to precisely identify and characterize peptide sequences. A typical
MS/MS-based proteomic experiment contains the following steps, as illustrated in
Figure 2.2: (1) protein digestion to produce shorter peptides; (2) peptide separation
by LC or other separation approaches; (3) analysis and detection of peptide ions;
(4) peptide selection for further fragmentation; (5) analysis and detection of peptide
9
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Figure 2.2: A typical MS/MS experiment procedure. (1) protein digestion; (2) pep-
tide separation; (3) survey scan generation; (4) peptide fragmentation; (5) MS/MS
spectrum generation.
fragment ions [168]. Two types of mass spectra are generated in such an MS/MS
experiment: survey scans and MS/MS spectra. Each survey scan has a retention
time, indicating the time in the LC experiment when the survey scan is taken. Each
peak in a survey scan denotes a peptide ion. Its m/z value reflects the mass of the
whole peptide but can not provide more information of the peptide sequence. The
subsequent fragmentation breaks a selected peptide to generate a series of fragment
ions, of which the m/z values are recorded in an MS/MS spectrum. Analysis of
MS/MS spectra, sometimes with the assistance of corresponding survey scans, can
help to identify peptide sequences and then determine the proteins in a biological
sample.
2.4 Peptide Fragmentation
In an MS/MS experiment, peptides are further fragmented to identify the sequences.
Peaks in an MS/MS spectrum represent a set of fragment ions generated from the
dissociation of a selected peptide. Theoretically, the peptide backbone can be broken
10
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Figure 2.3: Six types of fragment ions, i.e., a-, b-, c-, x-, y-, and z-ions, generated
through breaking the backbone of a peptide.
at any of three sites per residue to generate six types of fragment ions, as shown in
Figure 2.3.
Different fragmentation approaches emphasize the generation of different ion types.
Three fragmentation methods are commonly used in current MS/MS-based pro-
teomics: In collision-induced dissociation (CID), also known as collisionally activated
dissociation (CAD) [25], the peptide ions are usually accelerated by some electrical po-
tential to high kinetic energy and then collided with neutral molecules (often helium,
nitrogen or argon). In the collision some of the kinetic energy is converted into inter-
nal energy which results in bond breakage. Two types of fragment ions, b- and y-ions,
are frequently observed in MS/MS spectra obtained by CID fragmentation. In higher
energy collisional dissociation (HCD) [114], peptide ions are injected into a collision
cell and fragment ions are then analyzed by an Orbitrap analyzer. The mechanism of
HCD is similar to CID but more accurate m/z for the fragment ions can be measured.
HCD also generates b- and y-ions dominantly. When the higher energy is deployed, b-
ions can be further fragmented into a-ions or smaller species. Lastly, electron-transfer
dissociation (ETD), or electron-capture dissociation (ECD) [143], transfers electrons
to a multiply protonated peptide/protein, or generates radical cations for a multiply
protonated peptide/protein, and leads to the cleavage of the N–Cα backbone bonds
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Figure 2.4: An illustration showing the fragmentation pattern of glycopeptides.
to generate c- and z-ions. Ions derived from these ions, such as (c-1)- and z′-ions, are
also observed frequently in ETD (or ECD) spectral data [106, 171].
2.5 Glycopeptide Fragmentation
Glycosylation can decrease the fragmentation efficiency of peptide backbones when
collision based dissociation methods are used. For instance, fragmentation patterns of
glycopeptides are different from non-glycosylated peptides when using CID or HCD.
The collision energy is mainly absorbed by glycans. This leads to the glycosidic
bond breakages, while the peptide bonds are seldom broken. Thus, the fragment
ions generated by such approaches are dominantly B-, Y - and oxonium ions, as well
as some cross-ring fragment ions (A- and X-ions). The notations of fragment ions
generated from glycosidic bonds are different from the ones from peptide bonds (using
lower cases, e.g., b- and y-ions). The introduction of these notations can be found
in Domon and Costello nomenclature [37]. The breakages of glycosidic bonds in CID
or HCD fragmentation are illustrated in Figure 2.4. In contrast, ETD and ECD
dominantly produce fragment ions by breaking a peptide backbone but retain the
attaching glycan. Thus, glycans can be readily treated as normal PTMs with large
mass deviations in such case. The dominant types of fragment ions generated by
ETD (or ECD) for glycopeptides are c-, z-ions and their derived ions.
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2.6 Peptide Identification
Peptides are identified through interpreting MS/MS spectra data based on the prior
knowledge of common amino acids and PTMs. The 20 common amino acid residues
are listed in Table 2.2. The interpretation of an MS/MS spectrum seeks the best
matching peptide for the given spectrum. For example, in Figure 2.5, the peptide
YGFIEGHVVIPR is the best interpretation of the spectrum and its theoretical y-
ions generated from this peptide match all the significant peaks in the spectrum with
small mass errors.
In general, a peptide-spectrum match (PSM) score is calculated to measure the
similarity between a peptide candidate and a spectrum. A fragmentation site refers
to all types of ions generated from a fragmentation between two adjacent amino
acid residues. The peaks matched by a fragmentation site in the spectrum are used
to calculate a score for this fragmentation site, and the PSM score of a peptide
candidate is calculated from the combination of the scores at all the fragmentation
sites. The peptide candidate with the highest PSM score is finally selected as the
identification of the spectrum. The approach to calculate a PSM score is called a
scoring function, or a scoring scheme, which is the core part of the whole procedure
of peptide identification from a spectrum.
Database search and de novo sequencing are the two mainly used computational
approaches for spectral data interpretation. The major difference of these two ap-
proaches is the requirement of protein databases.
A database search approach requires the assistance of protein databases. The
protein sequences in a protein database are digested in silico to generate peptides,
then an MS/MS spectrum is compared with each possible peptide to calculate a PSM
score. The identification of the MS/MS spectrum is reported as the peptide from the
database with the top PSM score. The popular database search software packages
include Mascot [118], PEAKS [166], Sequest [41], MS-GFDB [78], X!Tandem [28],
and OMSSA [52].
In contrast, de novo sequencing constructs the peptide sequence directly from an
MS/MS spectrum, thus it is often used for novel protein identification. Rather than
searching peptides from a protein database, it searches all amino acid combinations to
find the optimal peptide sequence. Such searching is usually carried out by an efficient
dynamic programming algorithm to avoid the exponential running time. PEAKS
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Table 2.2: The 20 standard amino acid residues.
Name
3-letter 1-letter Monoisotopic Residue Residue
Symbol Symbol Mass Composition Structure
Alanine Ala A 71.037114 C3H5NO
Arginine Arg R 156.101111 C6H12N4O
Asparagine Asn N 114.042927 C4H6N2O2
Aspartic Acid Asp D 115.026943 C4H5NO3
Cysteine Cys C 103.009185 C3H5NOS
Glutamic Acid Glu E 129.042593 C5H7NO3
Glutamine Gln Q 128.058578 C5H8N2O2
Glycine Gly G 57.021464 C2H3NO
Histidine His H 137.058912 C6H7N3O
Isoleucine Ile I 113.084064 C6H11NO
Leucine Leu L 113.084064 C6H11NO
Lysine Lys K 128.094963 C6H12N2O
Methionine Met M 131.040485 C5H9NOS
Phenylalanine Phe F 147.068414 C9H9NO
Proline Pro P 97.052764 C5H7NO
Serine Ser S 87.032028 C3H5NO2
Threonine Thr T 101.047679 C4H7NO2
Tryptophan Trp W 186.079313 C11H10N2O
Tyrosine Tyr Y 163.06332 C9H9NO2
Valine Val V 99.068414 C5H9NO
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Figure 2.5: An example showing an annotated mass spectrum of peptide YG-
FIEGHVVIPR.
and PepNovo [45] are two state-of-the-art de novo software tools. Accurate de novo
sequencing, accompanied by different enzymatic digestions, has been proven to be
able to calculate the whole sequence for a purified protein sample [90]. However, the
accuracy obtained from de novo sequencing approaches is often lower than the one
obtained from database search approaches, thus there still exists much space for the
improvement of de novo sequencing.
Spectral library search is another type of computational approach for peptide
identification [29, 48, 83]. It requires a library of spectra that have been identified
previously. A spectrum is then searched in the library to find the most similar coun-
terpart, of which the corresponding peptide is reported as the search result. The
discussion of this method is out of the scope of this dissertation.
A major challenge in protein identification using these computational approaches
is introduced by the ubiquitous incorporation of hundreds of PTMs [39]. Most eu-
karyotic proteins are posttranslationally modified [159] and biochemists believe that
PTMs of a protein can help determine its activity state, localization, turnover, and
interactions with other proteins [100]. Therefore, precisely identifying modified pro-
teins and their PTM types, as well as locating the modification sites, are essential to
thoroughly understand their biological functions [8, 39, 100, 158]. So far, two common
PTM databases, DeltaMass [1] and Unimod [31], have recorded more than 300 and
600 types of PTMs, respectively.
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False positives unavoidably exist in the identification results because of the imper-
fect data and scoring functions. Researchers often use a false discovery rate (FDR)
to measure the error rate in the result. The target-decoy approach has been widely
used to validate the result by estimating the FDR [40]. In such a method, a random
database (the decoy database) is generated with similar statistical properties as the
target database. A database search approach is performed on both the target and
decoy databases. The FDR at a given score threshold is then estimated by the num-
ber of matches in the decoy database with scores above the threshold. Generally, the
decoy database is constructed by reversing the protein sequences in a target database,
but there is still no consensus in this community on the optimal way of using decoy
database. The target-decoy approach is doubted because of the pitfalls and dangers in
its applications [23, 56]; however, it is still prevalently used by researchers cautiously
and a modified target-decoy approach has also been proposed for two-pass database
search strategies [15].
2.7 Protein Quantification
Quantitative analysis of the proteins in a cell or tissue is another important application
in life science. After the identification of proteins in a sample, the expression level
of each protein can help to reveal more information about the protein’s participation
in a particular function or malfunction of the cell [65]. Protein quantification (also
known as quantitation) can provide a comprehensive description of the expression
level changes of the proteins under the influence of various perturbations, including
stress, infection, or disease. It can help identify biomarkers of particular diseases
and aid in an early diagnosis and intervention. Drug administration and therapeutic
effects could also be determined though protein quantification [116].
In an LC-MS experiment for peptide quantification, the peptides in a complex
sample are separated by LC according to their hydrophobicity and eluted at different
retention time. The m/z values of the co-eluting peptides are then measured by MS
and a mass spectrum (survey scan) at each scanned retention time is produced. Many
peptide features can be detected from a spectral dataset [165]. Each correctly detected
feature corresponds to a peptide in the sample and mainly consists of three pieces
of information: the mass, the retention time, and the signal intensity. For the same
peptide, the signal intensity is approximately proportional to the abundance of such
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peptide in the sample. Thus, if two features of the same peptide from two samples are
confidently matched, the quantity change of the peptide can be estimated from the
intensity ratio of the two matched features. The protein ratios can then be calculated
from corresponding peptide quantity changes.
Two major experimental approaches exist for peptide quantification: isotopic la-
beling and label-free [149]. In the isotopic labeling approach, two samples are labeled
with different isotopic reagents before being mixed together and then analyzed in a
single LC-MS experiment. Most commercially available labeling reagents do not in-
fluence the retention time of a peptide. The same peptide with different labels from
the two samples appear at almost the same retention time, making the match find-
ing computationally simple. Labeling quantification is not covered in this dissertation
and its detailed introduction is available in the literature [57, 115, 157]. The label-free
method does not label the samples and measures the two samples in separate LC-MS
runs. As the isotopic labeling step is not needed, the complexity of the experiment is
greatly reduced [113, 156]. Label-free quantification is becoming the most promising
method for the large-scale comparison of hundreds of samples that are required for
biomarker discovery [169].
Label-free quantification provides more computational challenges to bioinformati-
cians. The major problems encountered in a label-free quantification analysis include
peptide feature detection and matching, peptide ratio calculation, and protein ratio
calculation. In this dissertation, the peptide feature matching problem is addressed.
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Chapter 3
De Novo Sequencing with MS/MS
Spectrum Pairs
De novo sequencing is important for novel protein identification in MS/MS-based
proteome analysis. Nevertheless, current scientists admit that the peptides identified
by de novo sequencing are not as confident as those from database search approaches.
Higher quality MS/MS spectral data are generally required to obtain satisfactory
results in de novo sequencing. If some of the expected fragment ions are not produced
by the fragmentation, the corresponding peaks will be absent from the spectrum,
leading to ambiguity for the determination of some local segments of the peptide.
The ambiguity can often be eliminated in database searching, while it remains in de
novo sequencing and leads to a partially correct peptide. Thus, more information is
demanded to improve the identification accuracy, and it is essential to make de novo
sequencing more practical in proteomics research.
Development of various fragmentation approaches provides the possibility of us-
ing multiple fragmentation methods to reduce the ambiguity in de novo sequencing.
When a fragment ion is absent from one fragmentation method, a different type of
fragment ion corresponding to the same segment of residues may be produced in
another fragmentation, helping to retrieve the local peptide composition without am-
biguity. In addition, peaks from the multiple spectra can confirm each other, and
this can greatly increase the confidence in distinguishing a signal peak from noise.
Indeed, three de novo sequencing approaches have benefitted from the use of two
types of spectra acquired from different fragmentation methods [129, 35, 16].
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Savitski et al. [129] introduced the first de novo sequencing approach using two
complementary fragmentation techniques, CAD and ECD. In their method, a series
of simple criteria were used to determine the correct fragmentation sites from both
types of spectra. Datta et al. [35] computed the score of a fragmentation site by using
a TAN-structured Bayesian network which involved different fragment ions from two
types of spectra. This Bayesian network differs from the one used in PepNovo [45]
algorithm, in which the structure is hand-selected by a human expert. The advan-
tage of using a Bayesian network is that the correlation between different fragment
ion types is considered, but the intensity information has to be discarded since the
events in a Bayesian network are required to be discrete. Bertsch et al. [16] utilized
peak intensity in their scoring scheme: theoretical spectra were generated from pep-
tide candidates and then compared with the experimental spectrum. An accurate
predictor of the theoretical spectrum is required and the performance of such a scor-
ing scheme heavily depends on the accuracy of the spectrum predictor. However,
the implementation of such a spectrum predictor is extremely difficult because of the
complicated dissociation mechanism [96].
New de novo sequencing algorithms have been presented based on two types of
spectra in all these three approaches. Nevertheless, most existing de novo sequencing
algorithms [34, 45, 97] can also be easily applied on multiple types of spectra by
simply modifying their scoring functions. In this chapter, we propose a novel scoring
module, ADEPTS, to improve de novo sequencing performance by using CID/ETD
spectrum pairs. ADEPTS uses two models to incorporate peak intensity and ion type
information into the score, respectively. We show that ADEPTS increases the ability
to distinguish the true fragmentation sites from the false ones and finally improves
the result accuracy.
3.1 Methods
ADEPTS accepts a CID/ETD spectrum pair and a peptide candidate to calculate
their matching score. Different from traditional de novo sequencing approaches that
work only on spectra of a single type, ADEPTS uses both spectra when calculating
the score for a peptide candidate. ADEPTS is used in the following framework to
identify a spectrum pair:
1. Use the de novo sequencing module of PEAKS [97] to generate 1,000 peptide
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candidates for the CID and ETD spectrum, respectively;
2. Use ADEPTS to evaluate the match between each of the 2,000 peptide candi-
dates and the spectrum pair;
3. Report the peptide candidate with the top matching score.
The PEAKS de novo sequencing module in the first step can be replaced by
any other existing de novo sequencing software that can output multiple peptide
candidates from one spectrum, such as Lutefisk [148] or the algorithm proposed by Lu
and Chen [94]. The second step, in which the match between a peptide candidate and
a spectrum pair is evaluated, is the essential part of ADEPTS and briefly described
as follows:
1. Each peak in the two spectra is assigned a non-negative significance value;
2. For each peptide candidate:
(a) Calculate theoretical m/z values of each fragmentation site and match
them to peaks in the corresponding spectrum. The significance values of
matched peaks form a significance vector;
(b) Calculate a likelihood score vector from the significance vector, then use
a support vector regression (SVR) model to convert the score vector to a
score for the fragmentation site;
(c) Similar to 2(b), calculate an SVR score for each residue of the peptide
candidate;
(d) Add the scores for all fragmentation sites and all residues of a peptide
candidate to calculate the peptide score.
Each step is described in details in subsequent sections.
3.1.1 Peak Significance Value
To calculate the significance value of a peak in an MS/MS spectrum, four features
of the peak, the rank, the relative intensity, the local rank, and the local relative
intensity, are considered. This approach was proposed by Liu et al [91]. The rank
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Figure 3.1: Comparison of two approaches to incorporate peak intensities. The areas
under ROC curves represent the discriminative performance of using the significance
value and the relative intensity alone.
of a peak is the number of peaks in the spectrum with higher or the same intensity.
The relative intensity is the ratio between the average intensity of the top few peaks
in the spectrum and the intensity of the examined peak. The definition of the local
rank and the local relative intensity are the same as the rank and the relative intensity
respectively, except that only the peaks within ±56 Da from the examined peak are
considered rather than all the peaks in the spectrum. The peak significance value S
is defined as a linear combination of the logarithms of these four values:
S = c1 · lg(R) + c2 · lg(I) + c3 · lg(Rl) + c4 · lg(Il), (3.1)
where R, I, Rl, and Il denote the rank, the relative intensity, the local rank and the
local relative intensity, respectively. The coefficients (ci, 1 ≤ i ≤ 4) are trained from
an annotated training data set. According to this definition, a smaller significance
value indicates a stronger peak.
We preprocess the peaks in a spectrum, including centroiding, de-isotope and
de-convolute, using the data refine module of PEAKS and calculate the significance
value of each peak using Eq. 3.1. Receiver operating characteristic (ROC) analysis is
adopted to obtain the four coefficients c1, c2, c3, and c4. To generate the ROC curves,
the peaks matched by y- and b-ions (in CID spectra) or by c- and z′-ions (in ETD
spectra) are positives, and the peaks matched by randomly generated m/z values are
negatives. Changing the significance threshold with a minor step can generate a series
of true positive rate and false positive rate pairs, which are plotted as a ROC curve.
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Table 3.1: Frequencies of peaks matched by common fragment ion types in the train-
ing data.
CID
Ion Type y b y-H2O b-H2O b-NH3
Frequency (%) 52.4 47.3 31.9 31.7 27.6
Ion a y-NH3 a-NH3 z-H2O a-H2O
Frequency (%) 25.3 23.7 23.1 22.7 22.5
ETD
Ion Type c y z′ z′+1 c-NH3
Frequency (%) 56.6 50.4 42.6 32.4 31.6
Ion y-H2O z c-H2O x z
′-NH3
Frequency (%) 20.9 20.8 19.5 18.7 18.5
A larger area under the ROC curve (AUC) denotes a better discriminative power.
The four coefficients are trained using our training data to maximize the AUC.
Relative intensity is commonly used in scoring functions proposed in previous
research. Figure 3.1 illustrates a comparison on the discriminative power between
using the significance value and the relative intensity. It shows that the significance
value, which includes the other three terms of Eq. 3.1, performs much better than
relative peak intensity.
3.1.2 Likelihood Scores of Frequent Ion Types
Frequencies of peaks matched by several common ion types in our training data are
listed in Table 3.1. The most frequently observed fragment ion types induced by CID
and ETD are considered in ADEPTS: y, b, y-H2O, b-H2O, and b-NH3 ions for CID
spectra; c, y, z′, z′+1 and c-NH3 ions for ETD spectra.
A likelihood score function ft(·) is defined for each selected ion type t, and ft(x)
represents the score of a match between a type-t ion and a peak with a significance
value x.
The significance values of the matched peaks by type-t ions in the training data are
divided into four intervals, each of which contains the same number of the matched
peaks. The likelihood score at the centroid of each interval Ii, denoted by x
i
o, is then
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Figure 3.2: (a) The distributions of the peak significance for the true z′-ions and
random matches. (b) The z′-ion likelihood scoring function with respect to the sig-
nificance value.
calculated as
ft(x
i
o) = log
(
Pr(significance value falls in Ii | true site)
Pr(significance value falls in Ii | random site)
)
. (3.2)
The likelihood scores of significance values other than the centroid are computed by
linear interpolation. If a theoretical ion does not match any peak in the spectrum,
the likelihood score is calculated by
ft(null) = log
(
Pr(no peak matching | true site)
Pr(no peak matching | random site)
)
. (3.3)
For example, the distributions of the significance of z′-ion and random matches, as
well as the likelihood scoring function of the z′-ions, are illustrated in Figure 3.2.
3.1.3 Score for Each Fragmentation Site
A peptide candidate with n amino acid residues contains n − 1 fragmentation sites.
For each site i and ion type t, let the significance value of the matched peak be
xi,t. Then the likelihood score of this match is si,t = ft(xi,t), where ft is defined in
Section 3.1.2. The score of the fragmentation site i, denoted as si, is defined as the
linear combination of likelihood score of all ion types at this site,
si =
k∑
t=1
ct · si,t, (3.4)
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where k is the number of selected ion types, and c1, . . . , ck are constant coefficients
that are trained by an SVR model with the linear kernel.
The standard LIBSVM library [24] is used to train the SVR model. The training
of the coefficients maximizes the distinction between the fragmentation sites of true
peptide sequences and randomly generated peptide sequences using the training data.
3.1.4 Score for Each Residue
Each residue in the midst of a peptide sequence introduces two fragmentation sites at
both sides of the residue. In an MS/MS spectrum, there are often strong correlations
between the ions from two adjacent fragmentation sites. Figure 3.3 shows an example
of such a correlation. A residue score is thus used to incorporate this correlation into
the scoring function. For a specific ion type t, let xi and xi+1 be the significance
values of the two peaks at the two sites determined by a residue r, then the residue
significance value xr for this residue r and ion type t is defined as
xr,t =
√
(x2i + x
2
i+1)/2. (3.5)
Clearly, if xi + xi+1 is fixed, the smallest xr,t (smaller means more significant) is
achieved when xi = xi+1. Eq. 3.5 reflects that a residue in the midst of a peptide
candidate tends to be a correct one if it determines two same-type fragment ions that
match two peaks with similar significance values. This property results that a residue
having two adjacent ions with similar significance values obtains a higher likelihood
score. This score is used to represent the aforementioned correlation between ions.
Using the same procedure introduced to score a fragmentation site, the residue
significance values of different ion types form a likelihood score vector and then this
score vector is converted to a residue score sr using an SVR model.
3.1.5 Peptide Score
Given a peptide candidate P with n amino acid residues, let the scores calculated
for the n − 1 fragmentation sites be s1, . . ., sn−1, and the scores calculated for the
n− 2 non-boundary residues of the peptide be sr1, . . ., srn−2. The peptide score S(P )
is defined as
S(P ) =
n−1∑
i=1
si + λ ·
n−2∑
i=1
sri , (3.6)
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Figure 3.3: An annotated MS/MS spectrum that has stronger b-H2O ions for many
adjacent fragmentation sites, indicating strong correlation between the adjacent frag-
ment ions with the same ion type.
where λ is a positive coefficient that balances the weights of fragmentation site scores
and residue scores. In ADEPTS, the optimal λ is determined by performing a grid
search on the training data.
3.2 Experimental Results
ADEPTS was applied to two independent MS/MS data sets to evaluate its perfor-
mance. The first data set (LTQ-Orbitrap data set) was obtained from a Thermo
Fisher LTQ Orbitrap XL with ETD mass spectrometer (Thermo Fisher ScientificTM,
Bremen, Germany), and the second data set (Iontrap data set) was generated by an
ion trap mass spectrometer with implemented ETD module (Model HCTultra PTM
discovery system, Bruker Daltonik GmbH, Bremen, Germany). The second data
set was previously used by Bertsch et al. [16] to evaluate the performance of their
CompNovo software.
26
3.2. EXPERIMENTAL RESULTS
3.2.1 LTQ-Orbitrap Data Set
In this data set, the CID and ETD data were generated from two separate runs,
respectively. Therefore, CID/ETD spectrum pairs needed to be found before using
ADEPTS for the de novo sequencing.
In our experiment, we used PEAKS to find true spectrum pairs. The database
search module of PEAKS was applied separately to two types of spectra for the
identification of real peptide sequences, searching in the UniProt database [9]. A pair
of spectra from the two runs are considered as from the same peptide if: (1) the
two peptide sequences identified for both the CID and ETD spectra are the same;
(2) the PEAKS database search confidence score (−10 lgP ) is at least 60% on both
spectra; and (3) the two spectra have the same charge state and similar retention
time (subject to a fluctuation of at most ±10 minutes). The fairly large LC retention
time fluctuation (±10 minutes) is chosen since the same peptide in two runs is often
eluted at different retention time. The first two conditions ensured that the selected
CID and ETD spectra in a spectrum pairs are indeed from the same peptide with
high confidence. These selected spectrum pairs were regarded as the true spectrum
pairs with correct peptide sequences and used for the performance comparison among
several software tools later.
317 CID/ETD spectrum pairs with unique peptide sequences were obtained ac-
cording to the above criteria from the LTQ-Orbitrap data set. 148 of them were
randomly chosen as training data, and the remaining 169 were used as testing data.
The uniqueness of the peptides guaranteed that no peptide was in both training and
testing data. There were 2,291 amino acid residues in the training data and 2,648
residues in the testing data.
A fatal issue prevented the processing of these spectrum pairs by CompNovo.
Thus, ADEPTS was only compared with two state-of-the-art software tools, PepNovo
and PEAKS, on this data set. The major shortcoming of these two software tools
is that only one type of MS/MS spectrum is used to identify the peptide sequence.
PEAKS was used to analyze CID and ETD data in two different runs. PepNovo
(release 20091029) was only applied to the CID data for its lack of parameters for
ETD data analysis.
The precursor mass error tolerance and fragment error tolerance were 0.1 Da and
0.5 Da, respectively. The large fragment error tolerance is due to the measurement
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Table 3.2: Comparison between identifications of spectra in the LTQ-Orbitrap testing
data set. The first four rows are the percentage of the peptide sequences with at most
0, 1, 2, and 3 incorrect residues in the de novo sequencing results. The last row is the
percentage of the total correct residues.
PEAKS PEAKS PepNovo ADEPTS
TOTAL
(CID) (ETD) (CID) (CID+ETD)
Correct 12 10 8 32
169
peptides (7.1%) (5.9%) (4.7%) (18.9%)
≤ 1 incorrect 12 13 11 33
169
residue (7.1%) (7.7%) (6.5%) (19.5%)
≤ 2 incorrect 25 25 27 66
169
residues (14.8%) (14.8%) (16.0%) (39.1%)
≤ 3 incorrect 28 34 33 74
169
residues (16.6%) (20.1%) (19.5%) (43.8%)
Total correct 945 1,157 972 1,580
2,648
residues (35.7%) (43.7%) (36.7%) (59.7%)
of fragment ions using ion trap, which provides MS/MS spectra with relatively low
resolution as shown in Table 2.1. Table 3.2 illustrates that ADEPTS outperforms
both PEAKS and PepNovo on the number of correctly identified peptide sequences
and amino acid residues.
3.2.2 Iontrap Data Set
The Iontrap data set was previously published with PRIDE [73, 72] by Bertsch et
al. to evaluate the performance of their CompNovo software [16]. It contained 156
CID/ETD spectrum pairs as training data and 2,405 pairs 1 as testing data. The
total number of amino acid residues in the training and testing peptides were 1,906
and 32,186, respectively. The fragmentation pattern in this data set was quite differ-
ent from the one in the LTQ-Orbitrap data set. This difference was expected since
different types of mass spectrometers from different manufactures were used to collect
the MS/MS data.
1The testing data set originally contained 2,406 spectrum pairs as described in the paper of
CompNovo. One pair was removed in our experiment due to the different precursor m/z values.
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Table 3.3: Comparison of identifications on the spectra in the Iontrap testing data.
The first four rows are the percentage of the peptides with at most 0, 1, 2, and 3
incorrect residues in the de novo sequencing results. The last row is the percentage
of the total correct residues.
PEAKS PEAKS PepNovo CompNovo ADEPTS
TOTAL
(CID) (ETD) (CID) (CID/ETD) (CID/ETD)
Correct 286 57 63 676 820
2,405
peptides (11.9%) (2.4%) (2.6%) (28.1%) (34.1%)
≤ 1 incorrect 301 74 99 697 844
2,405
residue (12.5%) (3.1%) (4.1%) (29.0%) (35.1%)
≤ 2 incorrect 779 216 404 1,243 1,350
2,405
residues (32.4%) (9.0%) (16.8%) (51.7%) (56.1%)
≤ 3 incorrect 971 362 664 1,445 1,528
2,405
residues (40.4%) (15.1%) (27.6%) (60.1%) (63.5%)
Total correct 20,069 13,767 19,175 23,721 24,378
32,186
residues (62.4%) (42.8%) (59.6%) (73.7%) (75.7%)
We applied ADEPTS and other de novo sequencing software tools on the Iontrap
data set. The precursor and fragment mass error tolerance were set as 1.5 Da and
0.4 Da, respectively. We used the same tolerance values with the ones set in the
paper of CompNovo because of another failure of CompNovo on its own data set. 2
The de novo sequencing results published by Bertsch et al. in their paper were used
in the subsequent comparison. Table 3.3 summarizes the results of the comparison.
ADEPTS not only significantly beats the de novo sequencing accuracy of PEAKS
and PepNovo, but also performs noticeably better than CompNovo, which is specially
designed to do de novo sequencing using CID/ETD spectrum pairs.
Figure 3.4(a) compares the identification rates of different software as the function
of the number of allowed incorrect residues in each peptide. Figure 3.4(b) compares
the identification rates of different software as the function of the length of the longest
consecutively correct subsequence. Given a number of allowed incorrect residues or
a number of correct consecutive residues, a higher identification rate indicates better
performance achieved by a software tool. Clearly, as shown in Figure 3.4, software
tools that combine CID/ETD spectra pair (ADEPTS and CompNovo) perform signif-
2The running issue of CompNovo on its own data set was confirmed by its author after the
consultation.
29
CHAPTER 3. DE NOVO SEQUENCING WITH MS/MS SPECTRUM PAIRS
(a) (b)
Figure 3.4: (a) Identification rates of different software as the function of the number
of allowed incorrect residues for the testing data. (b) Identification rates of different
software as the function of the number of allowed incorrect residues for the testing
data.
icantly better than the ones that use only one type of spectra (PEAKS and PepNovo).
Furthermore, it is also illustrated that the performance of ADEPTS is noticeably bet-
ter than CompNovo.
3.3 Discussion
It is possible that any de novo sequencing tool that generates multiple peptide can-
didates can be adapted for candidate generation. We used PEAKS because it is
regarded as the most superior general de novo sequencing software with respect to
accuracy and efficiency [120], and it also supports de novo sequencing for both CID
and ETD. In addition, it has the capability of generating as many as 1,000 candi-
dates for each spectrum. This large number of the peptide candidate increases the
probability that the correct peptide is included and finally reported by ADEPTS,
since ADEPTS itself does not revise any peptide candidate. As shown in Section 3.2,
ADEPTS significantly outperforms PEAKS on both CID and ETD data interpre-
tation. This indicates the importance of the scoring function specially designed for
CID/ETD spectrum pairs. In addition, the peptide candidates are currently gener-
ated using CID and ETD separately. The performance might be further improved if
the candidates were generated from the spectrum pair, rather than only one spectrum.
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There are correlations between different ion types at the same fragmentation sites
and between two adjacent fragment ions with the same type. To better take account of
these correlations in a scoring function, the Bayesian network model used by Datta et
al. or PepNovo is more appropriate. However, this requires to discretize peak intensity
(or significance value), resulting in information loss and thus an apparent decrease
of result accuracy. In ADEPTS, instead of constructing a model to count in these
correlations directly, an SVR model is used to balance the weight of each type of ions
at the same fragmentation site, and the residue score defined in Section 3.1.4 is used
to reflect the correlations between adjacent fragment ions. Designing a model that
has the power of a Bayesian network but lacks the weakness induced by discretization
is still an open problem.
According to the guidance of correctly using LIBSVM given by Hsu et al. [69], both
the radial basis function (RBF) kernel and the linear kernel were tried in ADEPTS.
The parameters were optimized for both kernels and they achieved very similar per-
formance. We selected the linear kernel in our scoring function for its simplicity and
efficiency, conforming to Occam’s razor.
Instead of using the likelihood scores to form the vector for SVR score calcula-
tion, we also tried to use the peak significance values directly, but the accuracy was
remarkably reduced. This also indicates that the conversion from significance values
to likelihood scores is necessary.
Our method requires a CID/ETD spectrum pair from the same peptide. This can
be obtained either by (1) two separate LC-MS/MS runs of the same protein digest, or
by (2) programming the mass spectrometer to fragment the same precursor ion in two
consecutive scans using CID and ETD, respectively. For the first setting, some treat-
ments on the data are needed to obtain spectrum pairs. In general, data-dependent
acquisition (DDA) mode used in an MS/MS spectrometer for data collection favors
not fragmenting one peptide repeatedly, thus spectrum pairs can be readily selected
by a trivial procedure: given two spectra from CID and ETD respectively, they are
regarded to form a spectrum pair if they have similar precursor m/z values (the dif-
ference is less than or equal to a given threshold, e.g., 10 ppm for Orbitrap data) and
similar retention time. Moreover, the pairing of peptide features from two LC-MS
experiments is well studied in the label-free quantification method [139] and can be
readily facilitate the spectrum pair finding. For un-paired spectra, we can still use
the traditional de novo sequencing methods for the analysis.
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Chapter 4
De Novo Sequencing with Many
PTMs
The identification of post-translational modifications (PTMs) is of critical importance
in a study of protein functions. Novel proteins can be identified using de novo se-
quencing approaches, but identifying PTMs on the proteins is a nontrivial challenge.
Most de novo sequencing software tools allow users to specify only a few PTMs.
This limitation makes the peptides with unspecified PTMs become unidentifiable.
As pointed out by Duncan et al. [39], peptides with unspecified PTMs may be espe-
cially interesting, but unfortunately they are discarded due to limitations of existing
software.
A natural solution is to specify all the PTMs that possibly exist in a sample.
This approach only linearly increases the time complexity of commonly used de novo
sequencing algorithms. However, the consideration of a large number of PTM types
typically has a significantly negative impact on the result accuracy. De novo sequenc-
ing algorithms, such as PEAKS and PepNovo, tend to output peptide sequences with
many PTMs in such case, though most peptides identified in a proteomic study have
very few, if any, PTM occurrences in each peptide.
It is different between the number of PTM occurrences per peptide and the number
of PTM types specified to a de novo sequencing algorithm. Researchers usually do not
know all the PTM types in a peptide and thus have to specify a large number of PTM
types. However, only a limited number of PTMs can occur in a peptide. Therefore,
we develop a specialized de novo sequencing algorithm, DeNovoPTM, which allows
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the consideration of many PTM types, while limiting the number of PTM occurrences
in each peptide.
4.1 Problem Formulation
Let S be a given MS/MS spectrum. The total residue mass, M , of the peptide can
be derived from the precursor m/z and the charge of the spectrum. The spectrum
is usually provided with a peak list. Each peak (mi, hi) potentially corresponds to a
fragment ion, where mi represents the m/z value of the peaks and hi is its abundance.
Let Σ = {r1, ..., r|Σ|} be the alphabet of amino acid residues. Besides 20 unmodified
residues, this alphabet also includes modified residues that represent residues with
PTMs. Each residue ri has mass value m(ri). A peptide P is an sequence of amino
acid residues over alphabet Σ and m(P ) denotes the total mass of residues in P .
A scoring function F (P, S) is required to evaluate the similarity between a peptide
sequence P and a given MS/MS spectrum S, where a higher score means a higher
probability that the given spectrum is generated from the peptide.
The de novo sequencing approach involves constructing a peptide sequence P from
a spectrum S over the alphabet Σ, such that (1) the total residue mass is M and (2)
the similarity score F (P, S) is maximized. It is further required that the number of
modified residues in the computed peptide sequence P is upper-bounded by a given
number k. Formally, the de novo sequencing problem with a limited number of PTMs
per peptide (DeNovo-LPTM), given a scoring function F , is defined as follows:
DeNovo-LPTM
Instance: An MS/MS spectrum S, the precursor mass M , a residue alphabet Σ,
and a maximum number of PTMs per peptide k.
Objective: A peptide sequence P , over alphabet Σ, that satisfies: (1) the total
residue mass m(P ) is equal to M (within a specified error tolerance), (2) the number
of modified residues in P is no more than k, and (3) the similarity score F (P, S) is
maximized.
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4.2 Methods
In this section, the scoring function F (P, S) is introduced, and the algorithm for the
DeNovo-LPTM problem is then proposed.
4.2.1 Scoring Function
The scoring function we use for de novo sequencing here is similar to the one used by
ADEPTS, discussed in previous chapter, where a CID/ETD spectrum pair is used to
identify the target peptide. Here, the scoring function is slightly modified and applied
to CID spectra only.
Peaks in a spectrum are first assigned non-negative significance values using Equa-
tion 3.1. A match between a peak and a theoretical fragment ion of a proposed peptide
sequence contributes to the correctness of the corresponding peptide candidate. This
contribution is measured by a likelihood score according to its significance value and
the type of the matched fragment ion. A likelihood score vector for a fragmentation
site is generated and fed to a pre-trained SVR model to calculate the final score for
the corresponding fragmentation site. Thus, for each mass value m, a score f(m) can
be computed to represent the likelihood that the peptide has a prefix with the total
residue mass m. The fragmentation score of the peptide P is the sum of all scores at
all prefix mass values of the peptide.
In addition, our scoring function includes a penalty for each modified residue in
a peptide. If an MS/MS spectrum can be explained by two peptides, one has a
PTM but the other does not, with the same scores, we prefer the one without the
PTM [60, 127]. The value of this penalty should vary according to the frequency of the
specific PTM type being observed in a proteomic experiment. While our algorithm
can work for any user-defined penalties, the following configuration performs well in
our experiment. All PTMs in the Unimod database [31] were empirically classified
into four classes: common, less common, rare and very rare, and were assigned with
penalties of -0.15, -0.3, -0.45 and -0.6, respectively.1 For the sake of presentation, we
denote the penalty for a residue r by g(r). If r is an unmodified residue, g(r) = 0;
otherwise, g(r) < 0. The score F (P, S) is defined as the sum of the fragmentation
score and the PTM penalties.
1The classification and the four penalty values are configurable in the software.
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4.2.2 DeNovoPTM Algorithm
For a deconvoluted and de-isotoped spectrum, the m/z value of each peak is converted
to its nominal mass by multiplying 0.9995 and rounding to the nearest integer. The
constant 0.9995 is the average ratio between the nominal and the accurate mass of
the 20 basic amino acid residues [14, 67]. If more than one peak exist in an integer
bin, those peaks are treated as one and their corresponding intensity values are added
together as the new intensity. The total residue mass M is rounded into an integer in
the same way. Such integralization is to facilitate the use of a dynamic programming
algorithm for the de novo sequencing.
The score F (P, S) can be similarly defined on a partial sequence p of which the
total residue mass is less than M . For each mass m ≤ M , there is an optimal
partial sequences p with mass m such that the score F (p, S) is maximized. If there
are multiple partial sequences with mass m that maximize the score, any of them
satisfies our purpose.
Our algorithm maintains a (k + 1) by M matrix DP , in which DP (i,m) denotes
the optimal score that can be achieved by a partial sequence with mass m and i PTMs.
The optimal partial sequence p for DP (i,m) must be of the form p′r, consisting of
a prefix sequence p′ and a residue r ∈ Σ. It is clear that F (p, S) = F (p′, S) +
f(m) + g(r). Furthermore, p′ must also be the optimal partial sequence with its mass
m′ = m−m(r); otherwise, we can replace p′ by a better partial sequence to improve
the score of p, and this is a contradiction to the optimality of p.
Let Σ0 ⊂ Σ denote the set of unmodified residues in the alphabet, and Σ1 ⊂ Σ be
the set of modified residues. The following recurrence relation is explicit because of
the above discussion:
DP (i,m) = f(m) + max
{
maxr∈Σ0 DP (i,m−m(r))
maxr∈Σ1 DP (i− 1,m−m(r)) + g(r)
(4.1)
The dynamic programming algorithm for the DeNovo-LPTM problem, DeNovoPTM,
is shown in Algorithm 1. The time complexity of the DeNovoPTM algorithm is
O(kM |Σ|).
It is known that a de novo sequencing algorithm has a tendency to output a peptide
that matches the high peaks in the spectrum with multiple fragment ions [98, 34]. To
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Algorithm 1 DeNovoPTM algorithm to solve the DeNovo-LPTM problem.
Require: An MS/MS spectrum S, the precursor mass M , an unmodified residue set
Σ0, a modified residue set Σ1, and a maximum number of PTMs per peptide k.
1: function DeNovoPTM(S,M,Σ0,Σ1, k)
2: DP [i,m]← 0 for 0 ≤ i ≤ k + 1, 0 ≤ m ≤M
3: for i← 0 to k + 1 do
4: for m← 1 to M do
5: DP (i,m) = f(m) + max
{
maxr∈Σ0 DP (i,m−m(r))
maxr∈Σ1 DP (i− 1,m−m(r)) + g(r)
avoid this problem, the peptide reported by our algorithm is checked. If there is one
peak in the spectrum matched by both an N-terminal fragment ion and a C-terminal
fragment ion, we run the dynamic programming twice, in one run forbidding the
peak from being matched by an N-terminal, and in the other forbidding a C-terminal
fragment ion. If there are t significant peaks found to be matched by different ion
types, the algorithm is run 2t more times. In practice t is often 0 or a very small
integer. A similar strategy was also previously proposed in Mo et al [107].
4.3 Experiments and Results
We implemented our DeNovoPTM algorithm for de novo sequencing with a limited
number of PTMs. The performance of DeNovoPTM was evaluated by comparing with
two state-of-the-art de novo sequencing software tools, PEAKS (de novo sequencing
module) [98] and PepNovo (Release 20120423) [45], on two data sets: the ISB data
set and the PepSplice data set.
4.3.1 Performance Evaluation on the ISB Data Set
The MS/MS spectra came from the ISB (Institute for System Biology) standard
protein mixture data set [82], which is a standard protein data set for testing peptide
identification software tools. In our experiment, data from two LC-MS/MS runs for
the analysis of mixture 3 and 7 were selected. Mixture 3 was analyzed by an Agilent
37
CHAPTER 4. DE NOVO SEQUENCING WITH MANY PTMS
1100 system, while mixture 7 was analyzed by a Thermo Scientific Orbitrap MS/MS
spectrometer.
To determine the control set, we used the database search module of PEAKS
6 [166] to identify the peptide-spectrum matches (PSMs) with high confidence. Four
PTMs were used in the database search: carbamidomethylation on Cys, oxidation on
Met, deamidation on Asn and Gln, and phosphorylation on Ser, Thr and Tyr. All the
spectra were searched against the 18 standard proteins and the possible contaminant
proteins given by ISB. The reported modified PSMs are filtered using the following
rules: (1) PEAKS −10 lgP score of a PSM must be greater than 35; (2) a PSM must
have at least one cysteine carbamidomethylation or one phosphorylated amino acid;
(3) the precursor charge of the spectrum is 2; (4) for the PSMs with same peptides, we
keep the one with the highest −10 lgP score. After this strict filtration, 85 modified
PSMs with high confidence were obtained. These PSMs contained 1,094 residues,
with 120 modified residues.
We selected 71 frequently observed PTMs, using as common PTMs in PEAKS,
as possible PTMs in our experiment. All these PTMs were set as variable PTMs.
The number of PTM sites per peptide was limited to two in both PEAKS and
DeNovoPTM. PepNovo does not support such a limitation of PTM number, so no
limitation was specified.
To study the effect of the number of PTM types on the performance, each software
tool was run three times by specifying the four real PTMs mentioned above, the 38
PTMs in Table 4.1, and all 71 frequently observed PTMs in PEAKS, respectively.
Table 4.2 listed the comparison of three de novo sequencing tools in terms of the
number of residues and modified residues correctly reported by each tool. As a de
novo sequencing algorithm cannot distinguish two residues (or modified residues) with
the same mass, a reported residue (or modified residue) is regarded correct if its mass
is equal or similar (with mass error up to 0.1 Da) to the real possibly modified residue
at the same position of the peptide. Table 4.2 shows that DeNovoPTM outperforms
PEAKS and PepNovo on the number of correct PTM sites identified in all three
experiments. In terms of the number of correctly identified amino acids, PEAKS
performs the best when only four PTM types are used, while DeNovoPTM gets the
first rank in the experiments with 38 and 71 PTMs being specified. This indicates
the advantage of our algorithm when many PTM types are specified. Moreover, we
notice that the performance of PEAKS and PepNovo degrades significantly when the
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Table 4.1: Thirty-eight PTMs used to evaluate the performance of three de novo
sequencing software tool.
Index Mass Residues PTM Name
1 57.02 C Iodoacetamide derivative (C)
2 42.01 K, X@N-term Acetylation (K, X@N-term)
3 0.98 NQ Deamidation (NQ)
4 79.97 STY Phosphorylation (STY)
5 14.02 DE, X@C-term Methylation (DE, X@C-term)
6 15.99 M Oxidation (M)
7 79.96 Y O-Sulfonation (YTS)
8 42.05 RK tri-Methylation
9 -0.98 X@C-term Amidation
10 43.01 K, X@N-term Carbamylation (K, X@N-term)
11 43.99 EDKW Carboxylation
12 14.02 RK Methylation (RK)
13 -29.99 M@C-term Homoserine
14 -48.00 M@C-term Homoserine lactone
15 99.07 C N-isopropylcarboxamidomethyl
16 -18.01 C@N-term Dehydration (C@N-term)
17 71.04 C Acrylamide adduct (C)
18 39.99 C@N-term S-carbamoylmethylcysteine cyclization
19 -18.01 E@N-term Pyro-glu from E
20 -17.03 Q@N-term Pyro-glu from Q
21 21.98 DE, X@C-term Sodium adduct
22 105.06 C S-pyridylethylation
23 15.99 WH Oxidation or Hydroxylation (WH)
24 45.99 C Beta-methylthiolation (C)
25 42.02 K Guanidination
26 27.99 X@N-term Formylation (X@N-term)
27 44.03 C Ethanolation (C)
28 -17.03 C@N-term Loss of ammonia (C@N-term)
29 31.99 M dihydroxy
30 162.05 T Hexose (T)
31 203.08 N N-Acetylhexosamine (N)
32 210.20 CK, G@N-term Myristoylation
33 226.08 K, X@N-term Biotinylation
34 42.01 TSCYH Acetylation
35 227.13 C Applied Biosystems cleavable ICAT(TM) light
36 236.16 C Applied Biosystems cleavable ICAT(TM) heavy
37 0.98 R Deamidation (R)
38 27.99 TKS Formylation (TKS)
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Table 4.2: Comparison between the performances of three de novo sequencing software
tools on the ISB data set. Each software tool was run three times with 4 PTMs, 38
PTMs, and 71 PTMs being specified, respectively. This table listed the numbers of
PTMs that were identified correctly on both PTM types and positions, as well as the
numbers of correctly identified residues.
Software PEAKS PepNovo DeNovoPTM Real
Number of
4 38 71 4 38 71 4 38 71specified
PTMs
Number
120
of 78 41 24 64 50 41 79 65 61
correct (65%) (34%) (20%) (53%) (42%) (34%) (66%) (54%) (51%)
PTMs
Number
1,094
of 725 569 486 675 595 562 691 641 653
correct (66%) (50%) (44%) (62%) (54%) (51%) (63%) (59%) (60%)
residues
number of PTM types increases, whereas the performance of DeNovoPTM degrades
slowly.
4.3.2 Performance Evaluation on the PepSplice Data Set
To further evaluate performance, we applied DeNovoPTM to another data set ob-
tained from an ion trap MS/MS spectrometer. This data set was previously used
by Roos et al. in their PepSplice paper [127]. We downloaded the PepSplice data
set after the development of the DeNovoPTM software and the selection of the pa-
rameters; therefore, the test on this data set can be regarded as a blind test. The
MS/MS data were searched against the UniProt database [9] using the PTM search
module of PEAKS [60]. We used 0.5 Da as the precursor and fragment error tol-
erance, considering the low precision of ion trap instruments. Among the 195,314
MS/MS spectra, PEAKS identified 2,020 unique modified peptides with high confi-
dence (−10 lgP ≥ 35), including 12 types of PTMs. We used these 2,020 modified
PSMs as the control set in the subsequent evaluation.
The previously mentioned 71 PTMs were used as variable PTMs for three de
novo sequencing software tools: PEAKS, PepNovo, and DeNovoPTM. Two variable
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Table 4.3: Comparison between the performances of three de novo sequencing software
tools on the PepSplice data set. Each software tool was run three times with 4 PTMs,
38 PTMs, and 71 PTMs being specified, respectively. This table listed the numbers
of PTMs that were identified correctly on both PTM types, as well as the numbers
of correctly identified residues.
Software PEAKS PepNovo DeNovoPTM Real
Number of
4 38 71 4 38 71 4 38 71specified
PTMs
Number
2,672
of 425 245 165 433 336 267 415 390 366
correct (16%) (9%) (6%) (16%) (13%) (10%) (16%) (15%) (14%)
PTMs
Number
31,310
of 13,652 9,479 7,544 12,821 10,601 9,835 12,167 11,796 11,785
correct (44%) (30%) (24%) (41%) (34%) (31%) (39%) (38%) (38%)
residues
PTMs were allowed per peptide in both PEAKS and DeNovoPTM. The precursor and
fragment error tolerance values of all three software tools were set as 0.5 Da. Table 4.3
lists the performance comparison of these three software tools on this ion trap data
set. This comparison, similar to the previous one, shows that the performance of our
algorithm is the best compared with other two tools when many variable PTMs are
involved. Furthermore, it also shows that the performance of DeNovoPTM degrades
more slowly when the number of involved PTMs is increased.
4.4 Discussion
In this chapter, an efficient dynamic programming algorithm, DeNovoPTM, was pro-
posed and implemented for de novo sequencing. DeNovoPTM can be regarded as
a specialized de novo sequencing algorithm for a particular application. The exper-
imental results show that our algorithm outperforms two state-of-the-art de novo
sequencing algorithms, PEAKS and PepNovo, when the number of possible PTM
types is large. Particularly, the better performance comes from the ability to limit
the number of PTM sites per peptide in our algorithm.
In our study, the PTM types are unknown in advance, and researchers have to
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turn on many possible PTM types. This increases the solution space of the de novo
sequencing problem and leads to a higher chance of false positives and worse perfor-
mance of general tools. However, most peptides only contain a limited number of
PTM sites per peptide. Therefore, by using a specifically designed algorithm to limit
the number of PTM sites per peptide, our algorithm efficiently reduces the solution
space. This contributes to an improvement of de novo sequencing accuracy as shown
in the experimental section.
In some other situations, the researchers actually know additional information and
then special algorithms can be designed to achieve better performance by utilizing
more information than the general tools. For example, Bahtia et al. [17] added previ-
ously known peptide patterns to help improving the accuracy of de novo sequencing.
However, in many cases, the performance improvement is mostly due to the utiliza-
tion of the additional information or the correct handling of the lack of information.
It does not necessarily mean that the special tools will, or need to outperform the
general tools for all situations, and such a phenomenon has been shown in the two
performance comparisons.
The software implementation of our algorithm rounded all the mass values to the
nominal (integer) mass values. This will lose some information when a high resolution
mass spectrometer is used. However, the algorithm can be easily adjusted to utilize
the high mass accuracy through multiplying each mass value by a large integer before
the rounding.
Although there are more than 600 PTMs in the Unimod database, only 71 PTMs
used in our experiments are listed in PEAKS as the most commonly observed ones. In
theory all the PTMs in the Unimod database can be specified to DeNovoPTM; how-
ever, this is not recommended because of the serious reduction of de novo sequencing
accuracy. For the identification of rarely observed PTMs, we cannot solely rely on a
single MS/MS spectrum obtained in a high-throughput proteomic experiment.
Besides the de novo sequencing application, another possible application of De-
NovoPTM algorithm is to provide a short list of the most likely PTMs from a large
number of PTMs provided by users. The MS/MS data can be reanalyzed using a
traditional software tool by only considering the short list of PTMs.
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Database Search for Modified
Peptides Without Specifying
PTMs
During the past decades, many database search software tools have been developed for
peptide identification from MS/MS data [28, 41, 52, 118, 166]. However, these soft-
ware tools provide limited support to modified peptide identification using a straight-
forward procedure proposed by Yates et al. [164]: users specify the PTMs that possibly
exist in the sample. These search tools are regarded as conventional (or traditional)
database search engines.
PTMs specified by users are often categorized into fixed and variable PTMs. If
a PTM is specified as fixed, every occurrence of the residue will be replaced with
the modified residue and the consideration of these fixed PTMs will not affect the
software’s running time. In contrast, the consideration of variable PTMs dramatically
increases the workload of computing. In particular, many variable PTMs can modify
multiple amino acid residues in a peptide, easily causing an exponential growth of
search space.
The search space growth increases not only the running time, but also the potential
false discoveries to an unacceptable level. Therefore, when a conventional database
search engine is used for peptide identification, only a few variable PTMs can be
practically specified, while peptides with unspecified PTMs will not be reported.
Some researchers regard such limitation on conventional database search engines as
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one of the major factors that contribute to the current low identification rate of
MS/MS spectra [146] and the low characterization rate of modified peptides [39].
There exist software tools that have been developed for the identification of
unspecified PTMs. Many sequence tag-based tools, including the first tag-based
database search algorithm by Mann et al. [101], GutenTag [144], OpenSea [133] and
SPIDER [61], can be used to identify modified or mutated peptides from a protein
database. In these approaches, peptide sequence tags are generated from a spectrum
using de novo sequencing and then searched for the approximate matches in a protein
database. The differences between the tag and a matched peptide from the database
can be explained by either mutations or PTMs. InsPecT [146], MODi [79] and By-
Onic [14] employ hybrid search approaches: InsPecT speeds up the database search
through using partial de novo sequencing tags to select peptide candidates, whereas
the actual comparison between the spectrum and the peptide sequence is achieved
by a dynamic programming algorithm. The algorithm automatically finds the op-
timal mass shifts (possible PTMs) of the amino acids to most accurately align the
spectrum with the peptide. MODi applies a straightforward algorithm to search for
modified peptides in a protein database with at most 20 proteins. The small number
of proteins is insufficient for the study of complex protein mixtures. ByOnic uses
“lookup peaks” to extract peptide candidates from a protein database. Commercial
software tools such as the Paragon algorithm [135] and Mascot (Error Tolerant Search
Mode) [30] take a large number of PTMs in consideration during the search. To avoid
the combinatorial explosion of the search space, Paragon uses de novo sequencing tags
to locate “hot” areas in the protein database, where PTMs are intensively checked,
while Mascot only allows one type of PTM per peptide.
Several software tools have recently benefited from the discovery that many mod-
ified peptides have their unmodified forms (base forms) co-existing in the data. For
example, MS-Alignment [151] uses a dynamic programming algorithm to compare a
pair of spectra that are possibly generated by the modified and the base forms of a
peptide respectively. ModifiComb [130] uses the same principle except that a pair
of spectra is compared with each other only if one spectrum is identified as an un-
modified peptide. The retention time difference between the base and the modified
forms is also considered in ModifiComb. Another study [10] has further extended
this principle to form a spectral network using differently modified forms of the same
peptide.
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In this chapter we present a novel software tool, PeaksPTM, for modified peptide
identification without specifying PTMs. The first improvement is a default setting by
which the software considers all PTMs included in the Unimod database as variable
PTMs. We then add several search strategies to reduce the search space. The scoring
function in PeaksPTM uses the co-existence of modified and base forms of the same
peptide in a more effective way than either MS-Alignment or ModifiComb. Our
experiments show that PeaksPTM performs better on modified peptide identification
than four other state-of-the-art software tools.
5.1 Methods
PeaksPTM is designed for modified peptide identification from spectral data gener-
ated by typical LC-MS/MS experiments. It makes use of the high mass accuracy of
precursor ions from survey scans, generated from a high-resolution mass spectrometer.
The MS/MS data can be measured with a low-resolution mass analyzer.
PeaksPTM adopts a two-pass database search strategy. In the first pass, a tra-
ditional database search module identifies a list of possible proteins, with only a few
commonly observed PTMs specified. In the second pass, modified peptides from this
short list of proteins are checked for each spectrum with the consideration of all the
PTMs in the Unimod database. The computational analysis consists of four major
steps:
1. Protein identification. The MS/MS spectra are searched against a protein
database by PEAKS database search module for the identification of a short
list of protein candidates. This will filter out most impossible proteins to sig-
nificantly decrease the search space for the next step.
2. Single-PTM peptide candidate search. Protein candidates are digested in silico
into a set of peptide candidates. For each spectrum, an exhaustive search is
performed to find all corresponding peptide candidates with a limitation of
at most one variable PTM per peptide. This one-PTM-per-peptide limitation
avoids the exponential growth of the search space.
3. Peptide candidate rescoring. The peptide candidates for a spectrum are re-
scored by combining three features: the LDF score calculated by PEAKS, the
peptide pair and PTM rareness.
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• PEAKS LDF score. This score uses a linear discriminant function (LDF)
that involves three features: the PEAKS PSM score [97], the peptide length
and the average score of the 512 best PSM scores for the spectrum.
• Peptide pair. This feature examines a modified peptide candidate to de-
termine if its base form can be independently identified from another spec-
trum. The co-identification of both modified and base forms of the same
peptide increases the identification confidence.
• PTM rareness. A modified peptide with a rare PTM has to obtain a higher
PEAKS LDF score to receive the same level of confidence as a peptide
modified by a common PTM. This feature adjusts the score of a modified
peptide candidate according to the commonality of the PTM.
4. Multi-PTM peptide search. Common PTMs identified in single-PTM peptide
search are used to search for modified peptides with two or more PTMs.
PeaksPTM also controls result quality by a modified target-decoy approach, fol-
lowing the proposal designed for two-pass database search approaches by Bern et
al. [15]. Moreover, we also propose a straightforward and effective strategy to com-
bine the results from multiple search engines to further improve the identification
rate.
The details of the analytical steps, the features for rescoring, the quality control
of the result, and the consensus strategy are discussed in the following sections.
5.1.1 Protein Identification
A protein sequence is digested into a set of peptides. Only a partial set of the
peptides is fragmented and even less are identified by database search in an MS/MS
experiment. However, a protein from a database can still be identified even if only
a few peptides of the protein are identified. A short list of protein candidates can
thus be obtained by the base peptides and the modified peptides with specified PTMs
using PEAKS.
The database search is performed on a pre-constructed target-decoy database
to estimate the false discovery rate (FDR) of the identification result. The decoy
protein database is generated by shuﬄing each protein sequence in the target protein
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database. To shuﬄe a protein sequence, the amino acid residues between every two
adjacent digestion sites are randomly permutated, while the residue at the digestion
site is unchanged. If a shuﬄed peptide occurred in a target protein, it is removed from
the decoy database. The first-round database search on the target-decoy database
identifies a short list of protein candidates, including both target and decoy proteins.
A reduced protein database is constructed using these proteins for the subsequent
modified peptide search.
5.1.2 Single-PTM Peptide Candidate Search
Each protein in the reduced protein database is digested in silico to peptides, which
are regarded as base-form peptides. Single-PTM peptides are then generated by
replacing amino acid residues with modified ones. Suppose each amino acid residue
has m different PTMs on average in the Unimod database, then for a peptide with
length k, mk single-PTM peptides will be generated. This is only a linear growth on
the number of peptide candidates. Thus, a brute-force algorithm is used instead of
the sophisticated dynamic programming algorithm of InsPecT.
For each spectrum, a peptide candidate, either in base form or modified, is selected
for PEAKS PSM score calculation if the difference between the precursor mass of the
spectrum and that of the peptide candidate is within a specified mass error tolerance.
The top 512 peptide candidates according to the PEAKS PSM scores are selected
and each of them is further evaluated by the PEAKS LDF scoring function. The
peptide with the top LDF score is kept for each spectrum as its peptide candidate.
This peptide candidate for a spectrum can be either a base-form or a single-PTM
peptide.
5.1.3 Modified Peptide Rescoring
The peptide candidate of each spectrum is rescored since LDF score is originally
optimized for the identification of base-form peptides. To measure the match between
a modified peptide and a spectrum, the influence of the PTM in the candidate needs
to be considered. LDF scores help to determine peptide candidates for the spectra,
and other two features, peptide pair and PTM rareness, are used to take account of
PTMs in the peptide candidate.
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Figure 5.1: The LDF score distributions of single-PTM peptides identified from target
and decoy databases, respectively. (a) The distribution with peptide pairs, and (b)
without peptide pairs. Modified peptides from the target database tend to have more
peptide pairs than those from the decoy database.
Peptide Pairs
Similar to the observations in MS-Alignment [151] and ModifiComb [130], many pep-
tides have spectra in the data set for both their modified and base forms. It is natural
to conclude that if both forms of the same peptide are independently identified from
different spectra, the identification tends to be correct. This property is illustrated
in Figure 5.1 where the peptide pairs found in the target database are significantly
more than those found in the decoy database. This discovery is particularly relevant
to the modified peptide candidates identified with higher LDF scores and strongly
suggests the correctness of the above conclusion.
PeaksPTM uses this peptide pair feature by adding a reward to a modified peptide
identification if its base form is independently identified from another spectrum. The
reward addition occurs only after the peptide identification. This score adjustment
does not change the peptide result but only affects the decision to regard the result
as true or false when preparing the final report. This method is different from MS-
Alignment and ModifiComb, which use the base form in the identification of the
modified peptide. Compared to previous software, PeaksPTM appears to be less
sensitive since some modified peptides may not be identifiable by their spectrum
alone. However, the specificity of our method is much improved because it is very
rare that two independent identifications constitute both the base and modified forms
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Figure 5.2: The LDF score distributions of the peptide candidates identified with no
PTM, a common PTM, and a rare PTM, from (a) the target database and (b) the
decoy database.
of the same peptide unless both identifications are correct.
PTM Rareness
A rare PTM in a peptide typically demands a higher LDF score of the peptide to
justify its correctness, whereas common PTMs, such as oxidation on Met, are so
ubiquitous that their occurrence does not require a higher LDF score than the an
unmodified peptide. By summarizing the common PTMs reported in previous pub-
lications [100, 55], we regard the 29 PTMs in Table 5.1 as common PTMs, and all
other PTMs as rare ones.
Figure 5.2 shows the different LDF score distributions of the single-PTM peptide
candidates with different PTM types from the target and decoy proteins, respectively.
A great distinction is shown on this feature in the target peptides but not in the decoy
ones. It suggests a strong correlation between the PTM rareness and the identification
correctness.
Since there is no quantitative measurement for the frequency of each PTM type,
we use Ncommon ptm and Nrare ptm to denote the number of common and rare PTMs in
a peptide and penalties for both common and rare PTMs are obtained from training.
The penalty for a modified peptide, either with single PTM or multiple PTMs, is
actually the sum of the PTM penalties.
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Table 5.1: The summary of 29 PTMs which are frequently reported in previous
research.
Index Mass Residue Modification name
1 -48.003372 M@C-term Homoserine lactone
2 -29.992805 M@C-term Homoserine
3 -18.010565 C@N-term Dehydration
4 -18.010565 E@N-term Pyro-glu from E
5 -17.026548 C@N-term Loss of ammonia
6 -17.026548 Q@N-term Pyro-glu from Q
7 -0.984016 X@C-term Amidation
8 0.984016 N, Q Deamidation
9 14.01565 E, D, X@C-term Methylation
10 15.994915 W, H, M Oxidation or Hydroxylation
11 21.981943 D, E, X@C-term Sodium adduct
12 27.994915 X@N-term Formylation
13 31.989828 M Dihydroxy (Di-oxidation)
14 39.994915 C@N-term
S-carbamoylmethylcysteine cyclization
(N-terminus)
15 42.010567 K, X@N-term Acetylation
16 43.005814 K, X@N-term Carbamylation
17 44.026215 C Ethanolation
18 45.98772 C Beta-methylthiolation
19 57.021465 C Iodoacetamide derivative
20 58.005478 C Iodoacetic acid derivative
21 71.03712 C Acrylamide adduct
22 79.95682 Y, T, S O-Sulfonation
23 79.96633 Y, T, S Phosphorylation
24 99.06841 C N-isopropylcarboxamidomethyl
25 105.057846 C S-pyridylethylation
26 162.0528 S, T Hexose
27 203.0794 N N-Acetylhexosamine
28 210.19837 K, C, G@N-term Myristoylation
29 226.07759 K, X@N-term Biotinylation
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Weighted Sum Score
Our final score for a modified peptide candidate is a linear combination of four fea-
tures: the PEAKS LDF score (Sldf ), the existence of a peptide pair (Epeptide pair), the
number of common PTMs (Ncommon ptm), and the number of rare PTMs (Nrare ptm).
More specifically, the scoring function f(·) for calculating the score of a modified
peptide candidate P is defined as
f(P ) = Sldf + c1 · Epeptide pair − c2 ·Ncommon ptm − c3 ·Nrare ptm (5.1)
where Epeptide pair = 1 if there is a peptide pair; otherwise, Epeptide pair = 0. The
coefficients c1, c2, and c3 are obtained by training. This scoring function is also used
for rescoring modified peptides with multiple PTMs.
The obstacle to determine the coefficients ci is to find a training data set consisting
of a large number of spectra annotated by modified peptides. Manually annotating a
large-scale data set is impractical, while simulated data sets used in previous research
introduce difficulties to evaluate false negatives [146]. Alternatively, the coefficients
can be trained by maximizing the number of identifications at 1% FDR, which is
estimated with a target-decoy approach.
5.1.4 Estimation of the False Discovery Rate
The first-round database search on the target-decoy database identifies a short list of
protein candidates, including both target and decoy proteins. In general, the decoy
proteins in this short list are fewer than the target proteins, and this can result in an
underestimation of FDR after the second-round search.
A modified target-decoy strategy, which is specifically designed for two-pass database
search approaches, is adopted to avoid the underestimation of FDR [15]. In the first-
round search, a target-decoy protein database is searched to determine the possible
proteins. The reduced protein database is then constructed using the identified pro-
teins in the first-round search. It contains the target proteins (Pt), the decoy proteins
(Pd), and the shuﬄed proteins generated from Pt. The second-round database search
is performed on this reduced protein database to identify modified peptides. This
method is only slightly biased against target peptides and the estimated FDR will
not be lower than its actual value.
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The following method is used to calculate the FDR: suppose there are Nd identi-
fications from the decoy proteins and Nt identifications from the target proteins, the
FDR after removing the decoy hits from the results is then calculated as Nd/Nt.
5.2 Experiments and Results
We compared PeaksPTM with Mascot (Mascot 2.3, Error Tolerant Search Mode) [30],
Paragon (ProteinPilot software 4.0.8085, Paragon Algorithm: 4.0.0.0, 148083, trial
version) [135], and InsPecT (release 20101012) [146] on an MS/MS data set obtained
from human heart tissue. PEAKS was applied to generate the short lists of proteins
for PeaksPTM and InsPecT. In our experiments, we also compared PeaksPTM with
MODi [79].
5.2.1 Data Sets
Two data sets were involved in our experiments:
Human-heart: Heart tissue was homogenized with a Dounce homogenizer. The
proteins were reduced with DTT and alkylated by iodoacetamide, then digested by
trypsin overnight. The peptide mixture was separated via SurveyorT LC equipped
with MicroAST autosampler (Thermo Fisher ScientificTM, Bremen, Germany) using
a reversed phase analytical column. The data was collected with an LTQ Orbitrap
Velos mass spectrometer (Thermo Fisher ScientificTM, Bremen, Germany), consisting
of 11,207 survey scans and 15,117 MS/MS spectra.
Yeast: The yeast data set was generated from a fraction of Lys-C digest of a
yeast lysate by an LTQ Orbitrap XL mass spectrometer (Thermo Fisher ScientificTM,
Bremen, Germany). It contains 5,136 survey scans and 12,366 MS/MS spectra.
5.2.2 Coefficient Determination
The independent yeast data set was used to train the coefficients in Eq. 5.1 for the final
score calculation. This was to eliminate the overfitting problem caused by training
on the data sets from the same or similar species.
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Table 5.2: The numbers of identified peptides with FDR≤1% under different settings
of training and testing data sets.
Yeast (training) Human-heart (training)
Yeast (testing) 4,286 4,219
Human-heart (testing) 2,410 2,447
The performance by such training strategy was verified as shown in Table 5.2. The
parameters trained on one data set were used to identify the modified peptides from
the other. When the parameters trained on the Yeast data set were tested on the
Human-heart data set, the number of identifications at 1% FDR decreased from 4,286
to 4,219. Conversely, when the parameters trained from the Human-heart data set
were tested on the Yeast data set, the number of identifications decreased from 2,447
to 2,410. Using the training and testing data from the same species only produces
slightly better results than from different species. This indicates that the overfitting
problem in our method is negligible.
5.2.3 Comparison between Multiple Search Engines
PeaksPTM was compared with Mascot, Paragon and InsPecT to evaluate its per-
formance. As Mascot and Paragon have their own first-round search functions, the
IPI Human (v3.75) database, concatenated with its shuﬄed protein sequences, was
used as the target-decoy database. The corresponding FDRs were calculated using
the standard target-decoy approach [77, 75]. PeaksPTM used the same target-decoy
database and found 1,349 target and 773 decoy proteins. A reduced protein database
consisting of 3,471 entries was constructed as described above. InsPecT could not
finish the whole IPI human database in its blind search mode; therefore, it was ap-
plied on a list of 2,030 proteins identified by PEAKS from the target database. This
pre-selected protein list was believed to be a superset of the high abundance proteins
in the sample. Meanwhile, the decoy protein sequences generated from these 2,030
proteins were also searched to determine the FDR.
For PeaksPTM and Mascot, the precursor and fragment ion error tolerance values
were set to 10 ppm and 0.5 Da, respectively. The maximum variable PTM number
per peptide was set to 1 in PeaksPTM. For Paragon, we chose trypsin, Orbi/FT MS
(1 ∼ 3 ppm) LTQ MS/MS, biological modifications, and the thorough search mode
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Figure 5.3: The comparison of reported modified PSMs by InsPecT, Mascot, Paragon
and PeaksPTM. The curves show the relation between the estimated FDR and the
number of modified PSMs.
as the search engine configuration. For InsPecT, trypsin was designated, blind search
was turned on and the variable modification number was set to 1. The 15,117 MS/MS
spectra were split in two approximately equal batches for InsPecT to run in parallel
on two computing cores of an Intelr CoreTM i7 CPU with 2.80GHz. InsPecT used
21 CPU hours in total. Using the same computer, PeaksPTM, Paragon and Mascot
finished the analysis in approximately an hour, respectively.
With FDR below 1%, PeaksPTM reported 2,410 PSMs, 1,412 of which were mod-
ified PSMs; Mascot reported 1,331 PSMs and 729 modified PSMs, Paragon reported
1,972 PSMs and 1,029 modified PSMs, and InsPecT reported 1,133 PSMs and 521
modified PSMs. Figure 5.3 shows the performance comparison of these four soft-
ware tools on modified PSM identification. Even using a more strict FDR estimation
than the other three engines, PeaksPTM still performs significantly better than its
competitors.
We further investigated the composition of the reported modified PSMs by PeaksPTM
in Figure 5.4. Among the 1,412 modified PSMs, 761 (53.9%) were supported by at
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Figure 5.4: A large portion of modified PSMs reported by PeaksPTM with high
confidence (FDR≤1%) are also identified by at least one other engine, either with
high or low confidence.
least one other search engine with high confidence (with FDR≤1%). 449 (31.8%)
additional PSMs were supported by at least one other search engine regardless of the
confidence. As it is rare for two engines to falsely identify the same modified PSMs,
these consensus identifications are of high confidence.
5.2.4 Comparison with MODi
MODi identifies peptide sequences from a small database containing only at most
twenty proteins; therefore, ten top-scoring non-homologous proteins (out of the 1,349
target proteins from the first round search using PEAKS) and their shuﬄed sequences
were combined as the reduced protein database for MODi. All the PTMs provided
by the MODi web server were chosen as variable modifications and its default setting
for modified mass range (−150 ∼ 250 Da) was used. The InsPecT blind search can
also be used as a second-round PTM search tool, which accepts a reduced protein list
generated by any standard database search. Thus, InsPecT was also added to the
comparison with MODi. For a fair comparison InsPecT and PeaksPTM were both
used to search the same reduced protein database as MODi.
Figure 5.5 shows the comparison of these three software tools. PeaksPTM still
performs best in terms of modified PSM identification. It is noticeable that the FDR
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curves can only be used for the purpose of comparing these three tools, but may not
accurately reflect the real FDR values of the identifications because of the small size
of the target and decoy protein lists.
5.2.5 Consensus Strategy and Analysis
A consensus strategy can be applied to combine the identifications from multiple
search engines. A PSM is identified by either more than one search engine with
FDR≤ 1% or only one search engine with FDR≤ 0.8% is considered as a confident
identification.
Using this consensus strategy, 3,220 PSMs, including 1,965 modified PSMs, were
reported in total by these four search engines. The composition of these 1,965 modified
PSMs contributed by four search engines is illustrated in Figure 5.6. Two modified
peptides identified by different engines from the same spectrum are regarded as the
same if they have the same base form peptides, number of PTMs, and PTM mass
shifts. The determination of PTM sites was not considered in this consensus study.
The Venn diagram indicates that a large number (871) of modified PSMs were iden-
tified by two or more engines confidently and independently. This means that over
36% of all PSMs identified by any single search engine are modified PSMs. The large
portion of modified PSMs confirms the belief that the inefficiency in modified peptide
identification is one of the major factors for the low identification rate of the MS/MS
spectra [146] and the low characterization rate of the modified peptides [39].
5.2.6 Summary of Identified PTMs
Table 5.3 summarizes the frequent PTMs identified by PeaksPTM with 1% FDR
from the Human-heart data set. The same modified peptide identified from multiple
spectra is only counted once. There are 906 unique modified peptides identified by
PeaksPTM. Oxidation is the most frequent PTM, occurring on 200 peptides. The
utilization of the high resolution mass spectrometer enables PeaksPTM to identify
PTMs with small ∆m, such as deamidation (∆m = 0.98 Da), but it is still possible
that a PTM is mistakenly regarded as another one with the same or very similar ∆m.
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Figure 5.5: The comparison of PeaksPTM, MODi and InsPecT on the reduced
database with twenty proteins (ten target and ten decoy proteins). The curves show
the relation between the estimated FDR and the number of modified PSMs reported.
Figure 5.6: The Venn diagram shows the modified PSMs reported by applying the
consensus strategy on the results of four search engines.
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Table 5.3: The number of unique modified peptides containing the most common
PTMs in the Human-heart data set.
Mass (Da) Residues Modification PeaksPTM
-18.01 S, T, D Dehydration 10, 6, 8
-18.01 E@N-term Pyro-glu from E 12
-17.03 N Loss of ammonia 8
-17.03 Q@N-term Pyro-glu from Q 18
-2.02 S, T, Y 2-amino-3-oxo-butanoic acid 6, 4, 3
0.98 N, Q, R Deamidation 61, 39, 3
13.98 P Proline oxidation to pyroglutamic acid 4
14.02 E, D, S Methylation 84, 11, 5
15.00 N, Q Deamidation followed by a methylation 6, 7
15.99
M, Y, F, W,
Oxidation or Hydroxylation
99, 28, 25, 17,
H, P, N, K 11, 9, 6, 5
27.99
S, K, T,
Formylation
24, 6, 8,
X@N-term 15
28.03 E, D Ethylation 41, 7
31.99 M, W, P Dioxidation 23, 13, 10
42.01
S,
Acetylation
3
X@N-term 4
43.99 W, D Carboxylation 9, 1
47.98 C Cysteine oxidation to cysteic acid 15
57.02 C, K, H Carbamidomethylation 21, 3, 2
79.97 S Phosphorylation 4
58
5.3. DISCUSSION
5.3 Discussion
This chapter proposes our improved database search tool, PeaksPTM, used for mod-
ified peptide identification without specifying PTMs. PeaksPTM uses three features,
the PEAKS LDF score, the peptide pair, and the PTM rareness, to evaluate modified
PSMs. The peptide pair feature is more important according to our statistical anal-
ysis: 86.6% of the modified PSMs confidently identified by PeaksPTM have peptide
pairs. Compared to using the PEAKS LDF score alone, adding the peptide pair fea-
ture and the PTM rareness feature could identify 608 (35.9%) and 156 (9.2%) more
PSMs with FDR ≤ 1%, respectively, and adding both features improved 717 (42.4%)
identified PSMs.
The maximum allowed PTM number was set as 2 to search for the multi-PTM
peptides, with consideration of the PTMs summarized in Table 5.3. Only 32 new
modified PSMs were identified with high confidence (FDR ≤ 1%), while the running
time increased up to 3 hours. This experiment demonstrates that (1) the Human-heart
data set contains few heavily modified peptides, and (2) the time spent on database
searching with multiple PTMs is not negligible, even if only several variable PTMs
are considered. Only the single-PTM peptides were compared with the identifications
of other search engines in the experimental section.
PeaksPTM is not a blind-search engine that also attempts to find novel PTM
types, such as InsPecT. Using all PTM types in the Unimod database is sufficient
for most current proteomics research. In our experiment, InsPecT is able to identify
only one PTM with mass shift that does not match any existing PTM in the Unimod
database. Such identification definitely deserves a careful examination before it is
confirmed as a novel PTM. We recommend researchers choose different tools according
to their specific applications.
The target-decoy approach widely used today (and also used in PeaksPTM) can
only control the false positives a the peptide level, but not at the PTM level, which
includes the PTM identity and its location. Consequently, all the FDRs reported
in this study measure the correctness of the modified peptide sequence and the ∆m
of the PTM, but cannot ensure the correctness of the PTM sites reported by those
software tools. Accurately locating the PTM site is another nontrivial open problem.
It is commonly reckoned that the combination of different types of MS/MS data or
the significant improvement of instrument performance will facilitate the progress on
this research topic.
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Chapter 6
Identification of N-linked
Glycopeptides by Tandem Mass
Spectrometry
Glycosylation is an enzymatic process that attaches glycans to proteins, lipids, or
other organic molecules. It is one of the most frequently observed PTMs and more
than 50% eukaryotic proteins are predicted to be glycosylated [6]. Glycosylation of
proteins provides either specific structural function induced by conformation changes,
or specific recognition sites which are vital to cell-cell interactions [154, 161]. Addi-
tionally, increasing evidence suggests that some abnormal glycosylation is strongly
correlated with many diseases, such as cancer [80] and congenital disorders [47]. It
is commonly believed that these glycan-involved biological processes are closely re-
lated to specific glycan structures [32, 112, 153]. Thus, the accurate characterization
of glycoproteins, including the amino acid sequences, glycan structures (or compo-
sition), and glycosylation sites, is of great interest in the emerging glycoproteomics
field [117, 140].
Glycoproteome analysis is more challenging compared with conventional proteome
analysis, due to the variety of glycan structures and the complex linkages to proteins.
Three types of glycans have been reported: N -linked, O-linked and C-linked. Among
the three types, N -linked and O-linked are the most commonly observed ones. N -
linked glycans are dominantly found on the Asn residue within a consensus peptide
sequence, -Asn-Xxx-Ser/Thr-, where Xxx is any amino acid residue except Pro [51].
Furthermore, N -linked glycans share a single core structure, GlcNAc2Man3, derived
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from the same precursor GlcNAc2Man9Glc3 [70]. In contrast, O-linked glycans have
more varied core structures. This study focuses on the analysis of N -linked glycopep-
tides, including the identification of glycan composition as well as peptide sequences.
Tandem mass spectrometry (MS/MS) is the most powerful tool for the analysis
of the glycoproteome because of its high sensitivity and selectivity. In one approach,
glycopeptides are deglycosylated partially or totally using a specific glycosidase, such
as peptide N-endoglycosidase F (PNGase-F), and the resultant peptides and glycan
moieties are then analyzed separately by mass spectrometry [58, 59, 147, 167]. Al-
though this method simplifies the data interpretation, it is nontrivial to locate the
glycosylation sites for the identified glycans. Several strategies were proposed to
characterize intact glycopeptides by MS/MS experiments [103, 117, 162]. In ear-
lier experiments only one type of fragmentation method was used, typically CID, to
produce MS/MS spectra. Shortly afterwards, strategies of using a combination of
different fragmentation methods for intact glycopeptide analysis emerged. As men-
tioned in Chapter 2, CID and HCD mainly result in fragment ions through breaking
the glycosidic bonds, while ETD and ECD dominantly produce fragment ions by
breaking the peptide backbone but leaving the attached glycan intact. Combining
two complementary fragmentation techniques in MS/MS analysis enables the identi-
fication of peptide sequences, glycan composition, as well as the glycosylation sites
[3, 128, 132, 137].
Development of algorithms for automatically interpreting spectra acquired from
intact glycopeptides remains in its infancy [5, 126]. GlycoMod [26] is a web-based
tool to calculate all possible glycan compositions for a given mass. It does not use
the MS/MS data in the analysis. Glyco-Peakfinder [99] and GlycoFragments [92, 93]
can calculate the theoretical fragment ions of a given glycan structure, and use them
to annotate an MS/MS spectrum. However, these tools cannot identify glycopeptides
automatically and require a human expert to deduce the glycan structure. Glyco-
sidIQ [74], GlycoSearchMS [93] and GlycoWorkBench [22] accept a spectrum, search
glycan databases, and annotate the spectrum using glycan fragments. A peptide se-
quence has to be provided to these software tools in advance. This severely limits
the capacity for large-scale data analysis. Peptoonist [53], which is an extension of
Cartoonist [54], and GlypID 2.0 [104] search theoretical glycan structure databases
instead of a real database that comprises experimentally validated N -linked glycans.
Biologically validated rules are used for the generation of the theoretical glycan struc-
tures, but not all glycan structures reported in existing glycan databases are covered.
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GlycoPep Grader [160] and GlycoPep Detector [170] are web-based tools for assigning
the compositions of N -linked glycopeptides. However, only one MS/MS spectrum can
be processed at a time and users have to input the possible candidate compositions
for glycopeptides and glycans. Other software tools, such as STAT [50], Oscar [87],
StrOligo [42], GlycoMaster [134], and GLYCH [145], attempt to deduce the glycan
structures directly from MS/MS spectra using de novo sequencing approaches. These
tools typically require spectra with much higher quality for a reliable analysis. This
may potentially leave many spectra with medium quality un-interpreted in a high-
throughput experiment. A recent review by Dallas et al. discussed the current state
of glycopeptide assignment software in details and also pointed out the lack of soft-
ware that could analyze spectral data in batch for the unambiguous characterization
of N -linked glycopeptides [33].
The protein sequence databases commonly used in proteomics research seldom
record the glycan structure information for glycosylated proteins. For example, only
4,375 (21.6%) out of the 20,258 human proteins in the UniProt database contain
glycosylation site information. The percentage of glycoproteins is much lower than
expected. Thus it is nearly impossible to identify glycopeptides by searching a protein
database alone. On the other hand, databases for isolated glycan structures have re-
cently become available, such as CCSD/CarbBank [38, 131], CFG database [124], EU-
ROCarbDB [155], GLYCOSCIENCES.de [95], KEGG [76, 62] and GlycomeDB [125].
Therefore, it is theoretically possible to search a protein sequence database and a
glycan structure database simultaneously to characterize the glycopeptides from the
spectral data.
In this study, we implement a new software tool, GlycoMaster DB, for the auto-
mated and high-throughput characterization of intact N -linked glycopeptides from
MS/MS data generated by HCD/ETD or HCD-only fragmentation. The software
takes MS/MS spectra as input, searches in a given protein sequence database and an
integrated glycan structure database simultaneously, and reports the optimal peptide-
glycan pair that best matches each spectrum. Performance evaluations on four data
sets demonstrate the promising utility of the software.
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6.1 Methods
GlycoMaster DB processes MS/MS data from intact glycopeptides. Glycopeptides
can be fragmented by either HCD/ETD or HCD-only fragmentation. The HCD/ETD
protocol is preferred since the ETD spectra can be used to precisely identify glycopep-
tide sequences.
A short list of protein sequences needs to be specified by users in a FASTA file.
If the glycoproteins are not enriched or enriched at the protein level, a large number
of non-glycosylated peptides will be fragmented. Conventional database search tools,
such as PEAKS [166], Mascot [118] or Sequest [41], can identify the possible proteins
from these non-glycosylated peptides. If the enrichment is performed at the peptide
level, the proteins can be identified through separate experiments. The list of proteins
provided to GlycoMaster DB can be a mixture of glycosylated and non-glycosylated
proteins.
GlycoMaster DB integrates an N -linked glycan database extracted from the Gly-
comeDB database. If required, users can also easily append their own glycans data
into this database.
The GlycoMaster DB software analyzes the data in following three steps: (1)
filtration of glycopeptide spectra, (2) glycan assignment, and (3) peptide identifica-
tion. HCD spectra are used in the first two steps for glycan identification. The third
step determines the peptide sequences using either ETD data (if available) or the
calculated mass values of the peptides bearing the glycan.
6.1.1 Filtration of Glycopeptide Spectra
The input MS/MS data contains a mixture of spectra from both glycosylated and non-
glycosylated peptides if the sample is enriched on the protein level or not enriched.
GlycoMaster DB first selects out the spectra of glycosylated peptides since this can
help to improve the search speed and reduce false positives in later steps.
HCD spectra generated from N -linked glycopeptides have two types of character-
istics that are not frequently observed in the spectra of non-glycosylated peptides.
First, most spectra ofN -linked glycopeptides have two diagnostic peaks atm/z 204.09
and 366.14, corresponding to oxonium ions formed by a HexNAc and a disaccharide
Hex-HexNAc, respectively. Secondly, peaks of a glycopeptide form ion ladders in the
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high m/z region. The m/z values of two adjacent singly charged peaks in a ladder
differ by the mass of a monosaccharide residue, rather than the mass of an amino
acid. Both types of characteristics are used in the algorithm to select the probable
glycopeptide spectra. For each spectrum, the diagnostic peaks are first checked. The
presence of these two peaks triggers the subsequent examination on the existence
of peak ladders. By default, the spectrum is regarded as a glycopeptide spectrum
only if it has both the diagnostic peaks and a peaks ladder of length at least four
(corresponding to a sequence of three monosaccharide residues) in GlycoMaster DB.
Users can also specify the m/z values of diagnostic peaks and the minimum length
of monosaccharide ladders. Some glycopeptides only carry one HexNAc modification
and our filter will prevent the further analysis on such species. We argue that such
single glycosylation can be easily identified by setting HexNAc as a variable PTM in
conventional database search software packages.
We design a dynamic programming algorithm to compute the longest sequence of
monosaccharide residues that matches a series of high-intensity peaks in the spectrum.
In the algorithm, all the mass values are converted to the equivalent nominal mass by
multiplying a factor 0.9995 and then rounding to the nearest integers [14, 67]. After
the conversion, we select the highest 50 peaks of the spectrum to calculate the longest
sequence.
In a preprocessed spectrum, a sequence of monosaccharide residues is represented
by a series of peaks at m/z values m1, · · · ,mk+1, where (mi+1−mi), i ∈ [1, · · · , k], is
equal to the mass of a monosaccharide residue. The length of such a sequence is k. The
longest sequence of monosaccharide residues (LSMR) problem is to find the maximum
value of k in a given spectrum. Three most frequently observed monosaccharide
residues, Hex, HexNAc, and Fuc, are considered in this algorithm as the residue set.
Let L[m] be the length of the longest sequence that ends at mass m, and L[m] = −1
if there is no peak at mass m. If a peak is present at mass m, the algorithm needs
to check the existence of a shorter sequence ends at mass m0 such that (m − m0)
is equal to a monosaccharide residue mass. Such checking needs to be carried out
for each of the three given residues. Therefore, L[m] = maxi∈[1,3]L[m−m(ri)] + 1,
where m(ri) is the mass of the i-th monosaccharide residue ri. To summarize, the
algorithm MaxSeqLen shown in Algorithm 2 can compute L[m] for every mass value
m. The running time is linear to the precursor mass of the spectrum.
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Algorithm 2 The MaxTagLength algorithm for solving the longest sequence of
monosaccharide residues (LSMR) problem.
Require: An MS/MS spectrum S.
1: function MaxTagLength(S)
2: Let T [0]← −1
3: Let M ← the precursor mass of the spectrum S
4: for m← 1 to M do
5: if there is no peak at m then
6: T [m] = −1
7: else
8: T [m] = maxi∈[1,3] T [m−m(ri)] + 1
9: return maxm∈[1,M ] T [m]
6.1.2 Glycan Assignment
If a spectrum is regarded as a possible glycopeptide spectrum, the N -linked glycan
database is searched for its best matching glycan. Glycans that have smaller mass
than the precursor mass of the spectrum are matched to the spectrum. Each glycan-
spectrum match (GSM) is evaluated and the glycan with the highest score is reported.
The GSM scoring scheme is designed similarly to the ones commonly used for peptide
identification: (1) the theoretical m/z values of the possible fragment ions are calcu-
lated, (2) for each fragment ion, a reward or a penalty is added to the score depending
on whether its m/z value matches a peak in the spectrum. These two components
are described in the following two subsections, respectively.
Glycan Structure Fragmentation
As shown in Figure 2.4, HCD favors the fragmentation of glycosidic bonds rather
than the peptide bonds and produces B-, Y -, C-, and Z-ions [37]. In theory, a
breakage can also occur across the ring of a monosaccharide to produce A- and X-ions.
However, in practice, Y -ions are the most commonly observed ions in HCD spectral
data. Furthermore, peaks representing oxonium ions and B-ions can be observed in
the low m/z region, and in most cases, only those product ions with at most three
monosaccharide residues generate significant peaks. Therefore, B- and oxonium ions
with at most three monosaccharide residues, as well as Y -ions, are considered in our
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scoring scheme. GlycoMaster DB takes a condensed GlycoCT file in the GlycomeDB
database as input, parses it into a tree structure, and enumerates all the expected
B-, Y - and oxonium ions as discussed above.
The theoretical m/z values of the ions are calculated during the ion enumeration.
For example, for singly charged ions, the m/z value of a B- or oxonium ion is equal
to the total mass of the monosaccharide residues plus an additional proton, and the
m/z value of a Y -ion is equal to the singly charged precursor m/z value subtracting
the mass of the removed monosaccharide residues. The list of theoretical m/z values
and their corresponding fragment ion types are provided to our scoring scheme for
GSM evaluation.
Glycan-Spectrum Matching Score
In contrast with the development of PSM score in proteomics, the main challenge
for developing the scoring scheme for GSM is the lack of large-scale training data.
The proper values of the reward and penalty for a fragment ion matching and mis-
matching may depend on many factors such as the fragment ion type, the intensity
of the matching peak, and the mass error. In proteomics, these values are usually
statistically learned from a large number of training spectra annotated with known
results. Unfortunately, in the glycoproteomics field, such a large-scale training data
set is not yet available. Therefore, an empirical scoring function is used.
The scoring scheme in GlycoMaster DB calculates raw scores of GSMs first. Given
a glycan structure and a spectrum, the theoretical m/z values of the glycan fragment
ions are searched in the spectrum. The score S for a fragment ion matched by a peak
with relative intensity I is calculated using the following equation:
S =
{
lg (100× I), If a peak with relative intensity I ≥ 0.5% is matched
lg 0.5, Otherwise
(6.1)
The GSM raw score is the sum of all fragment ion scores. The glycan structure with
the highest GSM raw score is reported as the best match for the given spectrum.
The GSM raw score serves the purpose of selecting the best matching glycan
structure since a correct structure often produces more high-intensity matches and
generates a higher score than false structures. However, an incorrect GSM of a
spectrum with numerous peaks can easily get a higher raw score than a correct GSM
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of a spectrum with few peaks. Therefore, to compare the GSMs of different spectra,
the raw score is further normalized to a −10 lgP score, where P denotes the p-value.
A −10 lgP score represents the confidence of a GSM. Given a spectrum, the raw
scores of all glycans in the database are used to fit a normal distribution N (µ, σ2),
where µ and σ are the mean and the standard deviation of the GSM raw scores,
respectively. Each raw score x is used to compute a p-value P that denotes the prob-
ability in which a random variable under N (µ, σ2) exceeds x. The final GSM score is
−10 lgP and displayed in the result reported by GlycoMaster DB. The identification
results are sorted according to GSM scores. In our study, the reported glycan of which
the GSM score is no less than 15 (corresponding to a p-value of 3.2%) is regarded as
the plausible identification of a spectrum.
6.1.3 Glycopeptide Identification
GlycoMaster DB accepts two types of MS/MS data as input: HCD/ETD spectrum-
pairs and HCD-only spectra. Therefore, two different approaches for glycopeptide
identification were implemented separately.
Peptides cannot be identified from HCD spectra since few fragment ions from
the backbones are generated. In contrast, the ETD method dominantly produces
fragment ions by breaking a peptide backbone but leaving the attached glycan intact.
Thus, peptides are identified from ETD spectra in GlycoMaster DB when HCD/ETD
spectrum-pairs are available. The peptides containing the N -linked glycopeptide
motifs are generated first using the user-specified enzyme. For an ETD spectrum, a
peptide containing an N -linked glycopeptide motif and with mass smaller than the
spectrum’s precursor mass is considered as a candidate, and the mass difference is
regarded as the mass of the glycan. The peptide backbone fragment ions of each
glycopeptide candidate are then matched to the ETD spectrum to calculate a PSM
raw score. The Eq. 6.1 is used in the PSM raw score calculation with consideration of
c-, c-H, z-, z′- and z′′-ions. This raw score is then converted into a −10 lgP score as
the final PSM score, using the same procedure of the GSM score calculation. Then,
for each HCD/ETD spectrum-pair, the glycans obtained from the HCD spectrum and
the peptides from the ETD spectrum are combined together to build glycopeptides. A
glycopeptide is regarded as a probable identification to a spectrum if (1) the precursor
mass error is within the allowed mass error tolerance and (2) either the GSM score or
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the PSM score is greater than or equal to 15. If multiple glycopeptides satisfy these
two criteria, the one with the highest GSM score is kept in the main report, and the
others are stored in a secondary table that can be further examined by users. If no
peptide sequence is found for a spectrum-pair, the glycan with the top GSM score
from the HCD spectrum and a calculated peptide mass are reported.
If only HCD spectra are available, the peptide sequences are identified from two
sources of information: the calculated mass of the peptide and the existence of an
N -linked glycopeptide motif. The peptides containing such motifs are generated first
using the user-specified enzyme and stored in a sorted list in ascending order of
mass. GlycoMaster DB identifies glycans from an HCD spectrum and the glycan
with top GSM score (at least 15, which corresponds to a p-value of 3.2%) is kept
for later peptide determination. The difference between the precursor mass of the
spectrum and the mass of the top-scored glycan is the peptide mass. A binary search
is then applied to find peptides with this mass from the peptide list. The resultant
glycopeptides matching the spectrum precursor mass within the mass error tolerance
are reported as a list of possible peptides for the spectrum. If no peptide is found,
only the calculated peptide mass is reported.
6.2 Results
Four previously published data sets (Ribonuclease B, Human Immunoglobin G, Lectin-
Enriched Human Urinary Proteome, and Human Urinary Proteome) by Singh et
al. [137] and Marimuthu et al. [103] were used to evaluate the performance of Glyco-
Master DB. The first two data sets were obtained with HCD/ETD fragmentation and
thus glycopeptides could be characterized both on glycan composition and peptide
sequences. For the human urinary proteome data sets obtained with HCD fragmenta-
tion, GlycoMaster DB identified the glycan composition, while the peptide sequences
were reported only according to the calculated masses. Clearly, several peptides may
share the same mass value, resulting in peptide identification ambiguities if HCD-only
data is used. To study the severity of this ambiguity, statistical analysis by compu-
tational simulation was conducted and its results are illustrated at the end of this
section.
Experimental procedures for the sample preparation, glycoprotein enrichment and
LC-MS/MS analysis were described in details in Singh et al. [137] and Marimuthu et
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al [103]. Here, we briefly introduce the four data sets as follows:
Ribonuclease B (RNase-B) Data Set: This data set was from the study
of HCD product ion-triggered ETD (HCD PI ETD) analysis for characterization of
glycoproteins proposed by Singh et al [137]. Ribonuclease B (RNase B) from bovine
pancreas was digested using Lys-C. The digested peptides were separated using a
zwitterionic hydrophilic interaction liquid chromatography nano-column, and then
analyzed using LTQ-Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany).
The mass spectrometer performed a full survey scan with Orbitrap and subsequent
HCD MS/MS scans of the 40 most abundant ions. If peaks at m/z 204.09 (HexNAc
oxonium ions) or 366.14 (Hex-HexNAc oxonium ions) (±m/z 0.05) were within the
top 20 most abundant peaks, a supplemental activation ETD MS/MS scan of the
precursor ion in the linear ion trap was triggered. This data set contained 3,111 MS
spectra and 774 MS/MS spectra (632 HCD and 142 ETD spectra).
Human Immunoglobin G (Human-IgG) Data Set: This data set was from
HCD PI ETD analysis for characterization of glycopeptides in human IgG pro-
teins [137]. Human IgG is an antibody isotype and its fragment crystallizable region
bears a highly conserved N -linked glycosylation site. Four subclasses of human IgG,
IgG1, IgG2, IgG3, and IgG4, were present in this analysis. These proteins were di-
gested by trypsin and analyzed with the same HCD PI ETD strategy used for the
acquirement of the RNase-B data set. This data set comprised 952 MS spectra and
5,710 MS/MS spectra (5,436 HCD and 274 ETD spectra).
Lectin-Enriched Human Urinary Proteome (Enriched-HUP) Data Set:
This data set was from a comprehensive analysis of human urine proteome by Marimuthu
et al. [103] and contained 24 raw data files. The sample was incubated with a mix-
ture of three agarose conjugated lectins – concanavalin A, wheat germ agglutinin and
jacalin (Amersham BioSciences) – for glycoprotein enrichment. The concentrated
protein was then resolved by SDS-PAGE and visualized using colloidal Coomassie
staining. Twenty-four bands were excised and subjected to in-gel trypsin digestion
procedure and then analyzed using LTQ-Orbitrap Velos (Thermo Fisher Scientific,
Bremen, Germany) interfaced with an Agilent’s 1200 Series nanoflow LC system. The
mass spectrometry analysis was carried out in a data dependent mode with survey
scans acquired using Orbitrap mass analyzer, and 20 most abundant precursor ions
from a survey scan were selected for HCD MS/MS scans. This data set contained
22,886 MS spectra and 199,890 MS/MS spectra in total.
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Human Urinary Proteome (HUP) Data Set: This data set was also from
the comprehensive analysis of human urinary proteome and included 30 raw data files.
The sample was separated by SDS-PAGE without lectin-enrichment of glycoproteins.
Thirty gel bands were excised and subjected to in-gel trypsin digestion. The sample
analysis was carried out as described in the Enriched-HUP data set. This data set
included 35,788 MS spectra and 170,215 MS/MS spectra in total.
All four data sets were analyzed using PEAKS to identify the lists of proteins with
FDR ≤ 1%. The resultant proteins were exported as FASTA files for GlycoMaster DB
analyses. The RNase-B data set was searched against the UniProt bovine database
(5,973 entries), and the Human-IgG data set was searched against the UniProt hu-
man database (20,258 entries). Oxidation of Met was set as a variable PTM and
carbamidomethylation of Cys as a fixed PTM. The maximum allowed number of
missed-cleavages was set to two. The precursor and fragment error tolerances were
10 ppm and 0.1 Da, respectively. The two human urinary proteome data sets were
searched against UniProt human database (20,258 entries). Oxidation of Met, deami-
dation at Asn and Gln, and protein N-terminal acetylation were selected as variable
PTMs and carbamidomethylation of Cys as a fixed PTM. One missed-cleavage was
allowed for tryptic peptides. The precursor and fragment error tolerances were 20
ppm and 0.1 Da, respectively.
In subsequent GlycoMaster DB analyses, these four data sets were searched against
our integrated N -linked glycan database containing 2,925 unique N -linked glycans.
These glycans were extracted from the GlycomeDB database and two glycans were re-
garded as the same if they had the same tree structure but different linkages between
the monosaccharide residues. For each data set, the PTMs, the mass error tolerances
of precursor and fragment ions, and the maximum number of missed-cleavage were
set the same to the ones used in PEAKS analysis. Sodium and potassium adducts
were also considered in the search.
6.2.1 RNase-B Data Set
This data set was obtained using the HCD PI ETD strategy. HCD spectra were
preprocessed by the Data Refine module in PEAKS and thereafter used to identify
the short list of proteins. Among the 774 MS/MS spectra, 31 were identified as
non-glycosylated peptides with high confidence (−10 lgP ≥ 34.4 and FDR ≤ 1%)
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Figure 6.1: An example of the GlycoMaster DB result page generated in an
HCD/ETD spectral data analysis. The results are listed in a HTML table in descend-
ing order of glycan scores. Each row represents an identification of an HCD/ETD
spectrum pair. The first column includes a hyperlink that redirects to the top-ten
interpretations of the same HCD/ETD spectrum-pair. The second to the fifth col-
umn list the spectrum information. The sixth and the seventh column list the glycan
information obtained from the GlycomeDB database, and the hyperlinks redirect to
the GlycomeDB website. The eighth column gives scores of GSMs and each hyperlink
redirects to the annotated HCD spectrum and its mass error chart. The ninth and
tenth column list the peptide sequences and the PSM scores obtained from ETD spec-
tra. The hyperlink at the PSM score column links to the annotated ETD spectrum
and the mass error chart. The mass error between the theoretical and experimental
mass values of an identified glycopeptide is provided in the eleventh column. The last
column gives the accession numbers of corresponding proteins.
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Table 6.1: The grouped results identified by GlycoMaster DB from the RNase-B data
set. The spectra with the same precursor m/z and charge are grouped in a row if
they have the same identification. The GSM score, PSM score and mass error in a
row are from the HCD/ETD spectrum-pair with the highest GSM score.
Precursor Precursor
RT Range
Glycan GSM Glycan PSM Error
m/z Charge Composition Score Mass Score (ppm)
886.8996 2 27.06-28.21 HexNAc2Hex4 33.2 1054.37 55.2 -0.89
967.9255 2 20.13-29.67 HexNAc2Hex5 41.34 1216.43 73.44 -0.44
645.6194 3 19.79-28.54 HexNAc2Hex5 39.72 1216.43 45.04 -0.09
699.63715 3 24.74-29.21 HexNAc2Hex6 46.06 1378.49 52.65 -0.61
1048.9491 2 27.33-29.35 HexNAc2Hex6 36.62 1378.49 52.69 1.98
753.65375 3 27.56-29.59 HexNAc2Hex7 42.83 1540.54 40.01 0.65
1129.9783 2 29.27 HexNAc2Hex7 36.59 1540.54 82.64 -0.76
767.33167 3 28.31 HexNAc3Hex6 32.18 1581.57 34.22 -2.31
807.672 3 26.86-30.52 HexNAc2Hex8 50.72 1702.59 72 -0.38
861.6832 3 28.02-28.95 HexNAc2Hex9 50.48 1864.64 73.19 -0.57
and nine proteins were reported. HCD/ETD spectrum-pairs were then extracted for
glycopeptide analysis using GlycoMaster DB.
142 HCD/ETD spectrum-pairs were collected and 31 of these pairs were identified
by GlycoMaster DB. Figure 6.1 illustrates the result page of GlycoMaster DB on the
RNase-B data set (only the first four entries of the result are shown). The identified
glycans and peptide sequences are listed in a HTML table in descending order of the
glycan score. Users can easily check the annotated HCD or ETD spectrum and the
glycan information in the GlycomeDB database through the hyperlinks in the result
page. The 31 HCD/ETD spectrum-pairs identified by GlycoMaster DB have only
10 unique precursor m/z and charge combinations. Thus their results are grouped
and listed in Table 6.1. All these identifications share the single peptide sequence
SRNLTK.
Figure 6.2 illustrates an example of a glycopeptide identified from an HCD/ETD
spectrum-pair by GlycoMaster DB. Both the HCD spectrum and the triggered ETD
spectrum have a same precursor m/z value and similar retention time. Clearly, in the
HCD spectrum (Figure 6.2(a)), the peak ladder started from m/z 921.5 is definitely
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(a) HCD
(b) ETD
Figure 6.2: An example of a glycopeptide identified from the RNase-B data set gen-
erated by the HCD PI ETD strategy. (a) The annotated HCD spectrum of precursor
ions with m/z 807.672. GlycoMaster DB identified the best matched glycan with
the composition HexNAc2Hex8. SRNLTK is the only potential glycopeptide having
the similar mass to the calculated mass 699.404. (b) The annotated ETD spectrum
triggered by product ions in the HCD spectrum shown in (a). It provides positive
support for the identification of the peptide SRNLTK and the glycosylation site.
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from the Y -ions of the glycopeptide. A glycan with the composition HexNAc2Hex8
was reported by GlycoMaster DB as the best matching glycan with the highest GSM
score. The calculated mass of the peptide has only one peptide SRNLTK matched
within the given mass error tolerance in the nine proteins identified by PEAKS. For
the ETD spectrum as shown in Figure 6.2(b), GlycoMaster DB separately identified
the same peptide with the PSM score 72. Therefore, GlycoMaster DB reported
the glycopeptide SRN(HexNAc2Hex8)LTK as the identification of this HCD/ETD
spectrum-pair. The theoretical triply charged precursor m/z is 807.6717 and it differs
from the experimental precursor m/z with only 0.38 ppm.
As an optional step to further validate the peptide sequence, the PEAKS database
search software can be used to analyze the ETD spectra. A glycan of which the mass
has been determined by GlycoMaster DB is provided to PEAKS as a user-defined
variable PTM. PEAKS can check all the in silico digested peptides, rather than only
the peptides with N -linked glycopeptide motifs. Therefore, if the best matching
peptide for the ETD spectrum has an N -linked glycopeptide motif and its PSM score
is high, it is regarded as the identification of this ETD spectrum with high confidence.
We set all the glycans reported by GlycoMaster DB as variable PTMs for PEAKS
database search. Among 142 ETD mass spectra, PEAKS identified 31 spectra with
−10 lgP ≥ 15 and all of them were identified as the same peptide SRNLTK.
6.2.2 Human-IgG Data Set
Similarly to the analysis of the RNase-B data set, HCD spectra in the Human-IgG
data set were used to identify a short list of proteins. Among the 5,710 MS/MS spec-
tra, 306 were identified as non-glycosylated peptides and 36 proteins were reported.
HCD/ETD spectrum-pairs were then extracted for glycopeptide analysis using Gly-
coMaster DB. Out of the 274 HCD/ETD spectrum-pairs, 10 spectrum-pairs were
reported with either the GSM score or the PSM score higher than 15. The reported
glycopeptides are listed in Table 6.2.
Figure 6.3 illustrates a glycopeptide identified from an HCD/ETD spectrum-pair
by GlycoMaster DB. Figure 6.3(a) shows the HCD spectrum recorded at RT 18.49
min. The glycan reported by GlycoMaster DB has the composition HexNAc4Hex3Fuc1,
which forms a clear Y -ion ladder in the high m/z region. From the calculated mass of
the peptide, TKPREEQFNSTFR is selected as the possible peptide sequence. This
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(a) HCD
(b) ETD
Figure 6.3: An example of a glycopeptide identified from the Human-IgG data set
generated by the HCD PI ETD strategy. (a) The annotated HCD spectrum of precur-
sor ions with m/z 1028.7906. The best matched glycan reported by GlycoMaster DB
has the composition HexNAc4Hex3Fuc1. (b) The annotated ETD spectrum triggered
by product ions in the HCD spectrum shown in (a). It provides positive support for
the identification of peptide TKPREEQFNSTFR and the glycosylation site.
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peptide is also identified separately by GlycoMaster DB from the ETD spectrum
shown in Figure 6.3(b) with the highest PSM score. The difference between the
theoretical and the experimental m/z of this glycopeptide is 1.42 ppm.
PEAKS database search on the ETD mass spectra was further carried on to
validate the peptide identification reported by GlycoMaster DB. We set all the glycans
reported by GlycoMaster DB as variable PTMs for PEAKS database search. Among
274 ETD mass spectra, PEAKS reported 20 PSMs with FDR ≤ 1% and all the
peptides identified by GlycoMaster DB with GSM scores of higher than 15 were
included. PEAKS also identified nine non-glycosylated peptides, which matched to
both HCD and ETD mass spectra with high PSM scores. Manual checking revealed
that their HCD spectra had low peaks at m/z 204.09, which falsely triggered the
generation of the corresponding ETD spectra. However, these spectrum-pairs for
the non-glycosylated peptides did not result in false positives in GlycoMaster DB’s
results.
6.2.3 Enriched-HUP Data Set
This data set contains a large amount of spectra with duplicated precursor m/z and
similar retention time, indicating that many peptides were selected and fragmented
multiple times. Therefore, two MS/MS scans in this data set were merged with
the PEAKS software if their precursor m/z difference was within 20 ppm and the
retention time difference is within 0.2 minutes. The 24 spectral data files were then
searched separately in UniProt human protein database for the short lists of proteins
through identifying the non-glycosylated peptides and 503 proteins were reported. A
spectrum was filtered out if it was identified either by PEAKS DB with FDR ≤ 1%
or by PEAKS de novo sequencing with ALC ≥ 50% since it was believed to be from
a non-glycosylated peptide. The remaining MS/MS spectra were then analyzed by
GlycoMaster DB. The results from the 24 spectral data files are listed in Table 6.3.
In total, 14,840 spectra were not interpreted by either the database searching or
the de novo sequencing modules in PEAKS. These spectra were analyzed by Glyco-
Master DB. 2,283 spectra passed the first filtration according to the existence of diag-
nostic peaks at m/z 204.09 or 366.14, and 451 spectra had sequences of at least three
monosaccharide residues. These 451 spectra were searched against the N -linked gly-
can database. 240 spectra had matched glycans with high confidence (−10 lgP ≥ 15),
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Table 6.3: This table lists the analysis result of each spectral data in enriched-HUP
data set. The spectra data named “gpe12” is not listed since it has no glycan re-
ported by GlycoMaster DB. The first column lists the names of the spectral files.
The second column denotes the numbers of MS/MS spectra in each file after pre-
processing. The third and fourth column lists the numbers of proteins reported
by PEAKS DB and the numbers of un-interpreted spectra. The subsequent two
columns give the number of spectra that passed the two filters, respectively. The
number of identified glycans (−10 lgP ≥ 15) and peptides are listed in the last
columns. The last row shows the total number of each column.
Data MS/MS Protein Un-Interpreted Pass Pass Glycan Peptide
Name Number Number MS/MS Number Filter-1 Filter-2 Number Number
gpe01 1,635 53 604 109 12 10 10
gpe02 1,977 63 890 106 15 7 7
gpe03 1,821 65 798 99 17 6 6
gpe04 1,854 53 844 123 37 7 4
gpe05 1,920 59 832 107 31 20 18
gpe06 1,683 68 626 128 36 17 12
gpe07 1,866 100 835 108 14 6 6
gpe08 1,712 83 683 116 14 9 9
gpe09 1,777 77 788 112 10 8 8
gpe10 1,798 87 677 95 15 6 5
gpe11 1,999 86 906 210 12 4 4
gpe13 927 71 250 65 30 21 21
gpe14 929 65 301 84 38 17 13
gpe15 1,101 68 466 101 38 18 15
gpe16 1,290 91 559 68 21 14 14
gpe17 1,227 94 554 81 13 12 12
gpe18 1,282 88 597 93 26 16 16
gpe19 1,333 84 620 104 18 12 10
gpe20 1,234 81 619 106 23 6 5
gpe21 955 44 491 61 16 13 13
gpe22 977 79 482 68 8 6 4
gpe23 770 59 346 31 1 1 1
gpe24 1,117 65 711 90 6 4 3
Total 33,954 503a 14,840 2,283 451 240 216
aThis is the total number of unique proteins, rather than the sum of protein numbers reported
in each spectral data. 79
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and 216 of them had matched peptides by masses. Possible reasons for not reporting
peptide sequences for the 25 remaining spectra include (1) the peptides are not in
the 503 proteins identified by PEAKS and (2) the peptides may be the result of non-
specific trypsin digestion, have more missed-cleavages, or have variable PTMs other
than those considered. 95 proteins were reported as glycoproteins with at least one
glycopeptide identified by GlycoMaster DB in each protein.
Figure 6.4 shows three example glycopeptides identified by GlycoMaster DB. Fig-
ure 6.4(a) shows an MS/MS spectrum recorded at RT 30.03 min. The precursor m/z
1328.0316 corresponds to a doubly charged glycopeptide N(HexNAc2Hex9)WTITR
(m/zcalc = 1328.0299 and ∆m/z= −1.29 ppm). The peak at m/z 993.5 corresponds
to the singly charged [peptide+HexNAc] ion, which is the Y1 fragment according to
the Domon and Costello nomenclature [37]. Figure 6.4(b) and Figure 6.4(c) show
other two HCD spectra identified as having the same peptide sequence but slightly
different glycans. The differences between their precursor masses are the masses of
monosaccharide residues. As the retention time is mainly determined by the hy-
drophobicity of amino acids instead of the glycans attached on the glycopeptides, the
precursor ions of these spectra have similar retention time.
Figure 6.5 illustrates another example of two similar glycans on the same peptide.
The retention time of these two spectra differs by 2.7 min. The identified glycans
are very similar and SLHVPGLNK is the only glycopeptide that has the calculated
peptide mass. Consequently, the two spectra are very similar to each other, except
that Figure 6.5(b) contains two intense peaks at 292.10 and 274.09, which are missing
from Figure 6.5(a). These peaks demonstrate the existence of sialic acid residues. It is
commonly believed that sialic acids can influence the retention time of glycopeptides.
This is consistent with the 2.7 min retention time difference between the two spectra.
6.2.4 HUP Data Set
This data set was obtained from the same human urine sample as the Enriched-HUP
data set. The only difference was the glycoproteins were not enriched. GlycoMaster
DB was used to process this data set since many spectra contained high-intensity
diagnostic peaks of N -linked glycopeptides.
Similarly to the analysis of Enriched-HUP data set, the 30 spectral data files were
searched separately in UniProt human protein database for the short lists of proteins.
80
6.2. RESULTS
(a)
(b)
(c)
Figure 6.4: An example of glycans identified from three HCD spectra by GlycoMas-
ter DB in the Enriched-HUP data set. Three HCD spectra have similar retention
time but different precursor mass values. GlycoMaster DB identified three glycans.
The calculated peptide mass is approximate 771.41. NWTITR is the only tryptic
glycopeptide matching this mass value from the protein short list provided to Gly-
coMaster DB. The mass errors of the identifications of these three spectra are -1.29
ppm, -1.08 ppm, and -0.84 ppm, respectively.
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(a) SLHVPGLN(HexNAc4Hex5Fuc1)K, RT = 34.19 min
(b) SLHVPGLN(HexNAc4Hex5Fuc1NeuAc1)K, RT = 36.89 min
Figure 6.5: Illustration of two HCD mass spectra that are interpreted as the same
peptide but two slightly different glycans in the Enriched-HUP data set. (a) The
oxonium ions from sialic acids are not present, and this indicates the absence of sialic
acids in the glycan; (b) The peaks at m/z 292.10 and 274.09 indicate the existence of
oxonium ions of sialic acid residues.
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The number of identified proteins from each spectral file ranges between 61 and 362.
A spectrum was analyzed using GlycoMaster DB if it was not identified either by
PEAKS DB with FDR ≤ 1% or by PEAKS de novo sequencing with ALC ≥ 50%.
The results of those 30 spectral data were listed in Table 6.4. 337 spectra have
matched glycans with high confidence (−10 lgP ≥ 15), and 298 of them have found
corresponding peptide sequences from 229 proteins.
Figure 6.6 illustrates three example glycans identified by GlycoMaster DB from
this data set.
6.2.5 Comparison of Identified Glycans between Enriched-
HUP and HUP Data Sets
GlycoMaster DB identified 240 and 337 GSMs from Enriched-HUP and HUP data
sets, respectively. Since the peptide sequences were searched only according to the
calculated mass values, there might be ambiguities in the sequence identification.
Moreover, the best matching structure from GlycoMaster DB might not be the real
one because a spectrum could be matched equally well by several glycan structures
sharing the same composition. Thus, the identified glycopeptides were grouped ac-
cording to the combination of glycan composition and the peptide mass for each
human urinary proteome data set. These groups, instead of individual glycopeptides,
were compared to analyze the relationship of identified glycans between the two data
sets. 141 and 201 such glycopeptide groups were discovered from the Enriched-HUP
and HUP data set, respectively. Figure 6.7 is the Venn diagram that illustrates the
overlaps between these two sets of glycopeptide groups.
The comparison reveals that GlycoMaster DB can identify more glycopeptides
from the non-enriched data sets. The exact reason for this is unclear. But one prob-
able reason is the possible different instrument settings in the generation of the HUP
and Enriched-HUP data sets. In Enriched-HUP data set, a large number of MS/MS
spectra are from the repeated fragmentation of the same precursor ion. Consequently,
the total number of MS/MS scans is reduced from 199,890 to 33,954 after spectral
merging, or a 6-fold reduction. While in the HUP data set, the phenomenon of re-
peated fragmentation of the same precursor is less severe. After the spectral merging,
the reduction is from 170,215 to 72,152, or 2.4-fold.
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Table 6.4: This table lists the analysis result of each spectral data in HUP data
set. Only the 23 spectral data having identified glycans by GlycoMaster DB are
listed. The first column lists the names of the spectral files. The second column
denotes the numbers of MS/MS spectra in each file after preprocessing. The third
and fourth column lists the numbers of proteins reported by PEAKS DB and the
numbers of un-interpreted spectra. The subsequent two columns give the number
of spectra that passed the two filters, respectively. The number of identified glycans
−10 lgP ≥ 15) and peptides are listed in the last columns. The last row shows the
total number of each column.
Data MS/MS Protein Un-Interpreted Pass Pass Glycan Peptide
Name Number Number MS/MS Number Filter-1 Filter-2 Number Number
ig06 891 71 241 35 6 2 2
ig07 928 61 348 69 18 6 3
ig08 878 70 235 43 3 2 2
ig09 811 87 306 49 5 4 4
ig12 892 78 209 35 12 8 8
ig13 868 79 182 52 15 11 6
ig14 4,222 274 931 339 80 32 28
ig15 4,553 340 1,093 447 108 47 42
ig16 4,146 289 1,017 335 56 32 31
ig17 3,924 312 953 321 47 23 22
ig18 3,822 325 1,123 390 45 24 21
ig19 3,717 309 1,087 335 38 16 15
ig20 4,152 325 1,172 429 46 23 23
ig21 4,106 278 1,259 502 54 25 22
ig22 3,847 287 1,251 401 37 17 13
ig23 4,094 303 1,332 500 63 13 11
ig24 4,884 308 1,512 432 29 8 8
ig25 4,205 326 1,495 395 33 6 6
ig26 4,107 310 1,536 422 35 9 8
ig27 3,960 300 1,677 428 26 7 5
ig28 3,828 292 1,740 317 19 8 5
ig29 4,139 362 1,751 509 44 10 9
iga3 1,178 87 257 37 5 4 4
Total 72,152 1,534a 22,707 6,822 824 337 298
aThis is the total number of unique proteins, rather than the sum of protein numbers reported
in each spectral data. 84
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(a)
(b)
(c)
Figure 6.6: An example of glycans identified from three HCD spectra by GlycoMaster
DB in the HUP data set. Three HCD spectra have similar retention time but different
precursor mass values. GlycoMaster DB identified three glycans from them and these
glycans differ from each other slightly. The calculated peptide mass is approximate
1449.74. VYKPSAGNNSLYR is one of the two peptides matching this mass value in
the proteins provided to GlycoMaster DB but the other one has potassium adduct
and much larger mass error at around 10 ppm. Therefore, VYKPSAGNNSLYR is
selected as the glycopeptide and the precursor mass errors are 0.71 ppm, 0.08 ppm,
and -0.51 ppm, respectively.
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6.2.6 Glycopeptides with Same Mass
If only HCD data is available, the peptide is only reported according to the accurate
mass and the presence of N -linked glycopeptide motif. This may result in ambiguous
identification of the actual peptide when the size of the protein list is large or the
mass accuracy is low. Computer simulation was carried out to study the severity of
such ambiguity.
For each combination of mass accuracy (δ) and number (n) of proteins, n proteins
were randomly selected from the UniProt human database (20,258 entries). The tryp-
tic peptides containing the N -linked glycopeptide motif were generated in silico. The
percentage of such peptides with unique mass (mass error ≤ δ ppm) was calculated.
The random selection was repeated 1,000 times for each δ and n, and the average
percentage was plotted in Figure 6.8. It is noticeable that when the protein list con-
tains no more than 100 entries, and the mass accuracy is better than 5 ppm, 99%
of the tryptic peptides with the N -linked glycopeptide motif can be unambiguously
identified from the mass.
6.3 Discussion
The experiments demonstrate the feasibility of using GlycoMaster DB to identify
N -linked glycopeptides as well as the glycan structures (composition) from high-
throughput HCD/ETD and HCD-only MS/MS data. The software is designed for
the analysis of MS/MS data acquired from intact glycopeptides, rather than deglyco-
sylated glycopeptides. Therefore, it can simultaneously identify glycans and peptide
sequences. Such an application is important for large-scale glycoproteome analysis
since the connection between glycans and their peptides can be readily determined.
Figures 6.4, 6.5, and 6.6 illustrate multiple glycan forms on the same glycosylation
sites. This is useful information to facilitate the study of the glycan synthesis and
degradation process. In Figure 6.5, the different glycopeptides with the same peptide
sequence have slightly different retention time. It excludes the possibility that the
different forms are due to the post-source fragmentation in the mass spectrometer.
Most peaks in the HCD spectrum of a glycopeptide are from the fragmentation
of the glycan but not the peptide. This makes it difficult to confidently identify the
peptide sequence. Thus, a list of peptide sequences matching the calculated peptide
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Figure 6.7: The Venn diagram showing the overlaps between the two sets of glycopep-
tide groups identified from Enriched-HUP and HUP data sets, respectively.
Figure 6.8: The average percentage of tryptic peptides containing the N -linked gly-
copeptide motif that have unique mass.
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mass and containing the N -linked glycopeptide motif are reported. However, such
identification may be ambiguous when there are a large number of proteins, especially
when missed-cleavages and non-specific digestions were considered. The high mass
accuracy of the LTQ-Orbitrap instrument can greatly help to determine the accurate
precursor mass. In addition, the retention time of the glycopeptides is another piece
of potentially useful information. However, the lack of a reliable retention time pre-
diction algorithm for glycopeptides hinders the utilization of this information in our
software. Future versions of GlycoMaster DB will consider including the retention
time information when a glycopeptide retention time predictor becomes available. If
the glycopeptides are fragmented with both HCD and ETD, GlycoMaster DB can
use the spectrum-pairs simultaneously to identify both the glycans and the peptide
sequences with high confidence.
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Chapter 7
Maximum Peptide Feature
Matching in Label-Free
Quantification
The main difficulty of matching peptide features in a label-free quantification experi-
ment is the inadequate reproducibility of the LC retention time. Due to factors such
as aging, packing and contamination of an LC column, together with additional vari-
ability during experiment such as temperature, gradient shape and mixing physics,
the retention time from different runs often shows large shifts and distortions. To
match peptide features by using their mass and retention time information, the shifts
and distortions need to be corrected. This is usually carried out by finding a monoton-
ically increasing function f(·) that maps the retention time of a peptide in a sample
to the retention time of the same peptide in the other sample. This process is often
called the retention time alignment, or simply, time alignment [21, 86, 152].
It is noticeable that if the feature matching is available, the time alignment can be
solved by fitting the times of the matched features with a smooth function. On the
other hand, if the time alignment is known, the feature matching can be carried out
by comparing the mass and the corrected time differences between features in the two
samples. Although this is still not a trivial problem due to the existence of noise and
false feature pairs, its solution is not dauntingly difficult. The real challenge of the
feature matching problem lies in the mutual dependence between the time alignment
function and the feature matching.
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In the literature, the time alignment and the feature matching are usually dealt
with in two separate steps. Some research in the literature uses heuristic algorithms
to find an initial set of matched feature pairs, and then use these pairs to find a time
alignment function. Conversely, some research find a time alignment first and then
determine the matched feature pairs. Naturally, such procedures can be repeated
iteratively to hopefully get a more and more accurate result.
This approach was typified by Li et al. [88], which matched features with similar
m/z values as the initial feature matching. Kirchner et al. [81] used a robust point
matching method to find an initial feature matching, and then carried out smooth
monotone regression to find a time alignment. When there are significant time shifts
and distortions, as well as the present of noisy false features, the finding of the initial
set of feature matching in the above approaches can become challenging. However,
this problem can be solved if the peptides of all the features are known since the fea-
tures can be matched confidently by checking their peptide identities [44, 150]. This
approach requires MS/MS spectra for the identification of the peptides. MS/MS
analysis takes more duty cycles of the instrument. It reduces the number of MS scans
so that many of the low-abundance peptides from the limited amount of biological
samples become undetectable. Therefore, it is advantageous to perform quantification
without MS/MS if a time alignment can be achieved without peptide identification.
The peptides can be identified in a separate LC-MS/MS run after the quantification,
possibly with an inclusion list that targets the quantified peptide features. In fact,
there are even proposals in the literature to identify peptides purely based on the pre-
cursor m/z and the aligned retention time of a peptide feature [84]. This application
definitely requires the time alignment without MS/MS. For these reasons, we assume
the peptide identities are unknown to the alignment algorithm.
Other researchers focused on finding an initial time alignment function. Lange
et al. [85] assumed that the time alignment is a linear function: f(t) = a · t + b. A
pair of coefficients (ai, bi) was calculated from every two pairs of possibly matched
features. The correct coefficients (a, b) was estimated by finding a dense cluster of
all the calculated (ai, bi). However, the time alignment is actually nonlinear, so a
number of publications [13, 20, 71, 109, 122, 121, 123, 136] only assume local linearity
of the time alignment, and apply linear regression in small retention time intervals.
These studies mostly differ at the methods used for (1) local linear regression, and (2)
connecting the local linear regression results into a global time alignment function.
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Although many of these methods have been used in practice, none of them defined
a clear optimization goal for the peptide feature matching problem. There usually
exist biological justifications for each step of these methods, but the property of the
final output of a method is unclear. It is very different from the common practice
in traditional algorithmic research, where the optimization goal is usually specified
mathematically before the algorithm is being developed. Still, it is not uncommon in
many emerging bioinformatics areas (including peptide quantification) that biologists
often need a quick solution once an experimental method is invented. In such case
an ad hoc solution is always useful. Moreover, the complexity of biology determines
that the formulation of a tidy mathematical model is often difficult.
Disadvantages certainly exist in such ad hoc solutions. An immediate disadvan-
tage is that the final outcome is unpredictable without running such an algorithm.
The performance of the algorithm heavily depends on its implementation, such as the
choice of parameters and the handling of some special cases. Therefore, a method
developed in one lab has the tendency to get overfitting on its own data and may
not work on the data from another lab or a new instrument. This recommended
that a combinatorial problem should be clearly defined whenever it is possible. The
separation of the problem formulation, the algorithm development, and the program
implementation can help reduce the aforementioned overfitting tendency. The bio-
logical knowledge should be used exclusively during the problem formulation stage
to specify the desired property of the solution. The algorithm development should
strive to compute a solution that meets the specified property, instead of fitting the
data that happen to be available for a researcher.
In this chapter, a clearly-defined combinatorial model for the feature matching
problem is proposed in Section 7.1. The problem is proven to be NP -hard in Sec-
tion 7.2. In Section 7.3, a slightly modified optimization goal is proposed, under
which a polynomial time algorithm is presented. We show that the solution of the
modified problem helps to determine an upper-bound and a lower-bound of the opti-
mal solution. This results in a practical algorithm for the feature matching problem
with a performance guarantee for each given instance. In Section 7.4, the optimiza-
tion goal is amended to control the smoothness of the time alignment function for
feature matching and a polynomial time algorithm is presented. Finally, Section 7.5
examined the performance of the algorithms on real LC-MS data. Not only is the
proposed model tidy, but the performance of the algorithms also compares favorably
with other existing methods.
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7.1 The Maximum Feature Matching Problem
The peptide feature matching problem is formulated as a combinatorial optimization
problem in this section. A peptide feature p is a 2-tuple (m(p), t(p)), where m(p)
indicates the mass and t(p) indicates the retention time. We assume both m(p) and
t(p) are integers since real numbers can be discretized by allowing a small rounding
error. A sample consists of a set of features {p1, p2, . . . , pn}. Let S and S ′ be two
samples and their retention time ranges from 1 to T . A time alignment function
that maps the time of S to the time of S ′ is a monotonically non-decreasing function
f : [1, T ] 7→ [1, T ] such that f(1) = 1 and f(T ) = T .
As aforementioned, the retention time of a peptide cannot be measured accu-
rately. First, the unavoidable variations of LC conditions in the two MS runs can
cause systematic drifts of the retention time for all peptides. This systematic error
is modeled by the time alignment function f . Secondly, the retention time of an
individual peptide may change independently from other peptides, causing a random
error. Suppose two features p ∈ S and p′ ∈ S ′ are from the same peptide, the random
error is then modeled as |t(p′)−f (t(p)) |. After a proper time alignment, the random
error is usually small. For example, if two LC runs are conducted on the same LC
instrument under the same experimental condition and each lasts for an hour, the
random error is often less than 1 minute after the time alignment.
For every two features p ∈ S and p′ ∈ S ′, the matching quality of p and p′ is
measured by nonnegative function w(δm, δt), where δm = |m(p′) − m(p)| and δt =
|t(p′) − f(t(p))|. The function w is also called a weight function. The unit weight
function, denoted by wI , is a straightforward definition of the weight function. Let
∆m ≥ 0 and ∆t ≥ 0 be the mass and time error tolerances, respectively. The unit
weight function is then defined as
wI(δm, δt) =
{
1, if δm ≤ ∆m and δt ≤ ∆t,
0, otherwise.
(7.1)
The unit weight function treats a pair of features as a match if and only if their mass
and time differences are within the error tolerances.
A peptide feature matching, or simply, a feature matching, is a bijective mapping
between two subsets P ⊂ S and P ′ ⊂ S ′. More specifically, a feature matching
provides a set of feature pairs, M ⊂ {(p, p′)|p ∈ S, p′ ∈ S ′}, such that each feature
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appears in at most one pair in M . Given a time alignment function f and a weight
function w, the total weight of the matching M , is defined as
w(M) =
∑
(p,p′)∈M
w (|m(p′)−m(p)|, |t(p′)− f(t(p))|) . (7.2)
For label-free quantification, the two studied samples share most of their peptides
and the biological experiments are optimized to minimize the noise and the mass
and retention time errors. When the peptide identities for the peptide features are
unknown, the most natural combinatorial goal for peptide feature matching is to
maximize the total weight of the matching.
The maximum feature matching problem (MFM) is therefore defined as follows:
Given two samples S and S ′ and a weight function w, find a time alignment function
f and a feature matching M , such that w(M) is maximized.
It can be noted that if f is given, MFM can be easily reduced to the maximum
matching problem in a bipartite graph. In the reduction, each feature corresponds
to a vertex and the two feature sets S and S ′ can be regarded as the two vertex sets
of the graph. The weight of the edge between each feature pair is defined by the
weight function w. In particular, when w is the unit weight function, the reduction
results in the unweighted version of the maximum matching problem. It is well known
that polynomial time algorithms exist for both weighted and unweighted maximum
matching [46, 108]. However, for MFM, the time alignment function f needs to be
computed simultaneously with the feature matching, and this makes MFM a much
harder problem.
7.2 Maximum Feature Matching Is NP-Hard
Theorem 7.2.1 The MFM problem is NP -hard under the unit weight function.
Proof. The reduction is from the max-cut problem. Given an undirected graph
G = 〈V,E〉, the max-cut problem splits the vertices into two disjoint sets V1 and V2,
such that |{(u, v) ∈ E |u ∈ V1, v ∈ V2}| is maximized. It is well known that the
max-cut problem is NP-complete [49].
Let G = 〈V,E〉 be an instance of the max-cut problem. Let n = |V | and m = |E|.
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For presentation clarity, a feature is visually shown as a data point on a mass-time
grid (Figure 7.1). Each horizontal line on the plane corresponds to one time unit in
the LC-MS experiment, and each vertical line corresponds to a mass unit. As MFM
involves two samples S and S ′, two colors, black and white, are used to distinguish
the features in S and S ′, respectively. A black feature is represented by a solid dot
and a white feature is represented by a circle. It is possible that two features from S
and S ′ have the same mass and time, and in such case the grid point is labeled with
both a circle and a solid dot. Intuitively, MFM needs to match the black features onto
the white features, allowing a small mass and time error after the time alignment.
The time alignment can move all the black features on the same horizontal line up
and down simultaneously, but it cannot change the relative time order of the black
features.
The constructed instance of MFM consists of T = 6n+ 3 time units and 6m mass
units. Each edge ek ∈ E corresponds to a mass window of length 6, and each vertex vi
corresponds to a time window of length 6. The first and last time units are specially
added and do not belong to any vertex time window. Figure 7.2 illustrates the
construction that highlights edge ek and vertex vi. In the construction, many pairs of
black and white features are added to certain grid points as shown in Figure 7.2. More
precisely, a pair of black and white features are put at the grid point (6k − 3, 6i− 4)
for each 1 ≤ k ≤ m+ 1 and 1 ≤ i ≤ n+ 1. Additionally, for each edge ek, two white
features are put at (6k − 4, 1) and (6k − 4, T ), respectively. The construction of the
shaded areas in Figure 7.2 will depend on whether vi is adjacent to ek. Three cases
arise: (1) ek = (vi, vj) and i < j; (2) ek = (vj, vi) and i > j; and (3) vi is not adjacent
to ek. For each of the three cases, the construction of the shaded area is shown in
Figure 7.3. Finally, we set the mass and time error tolerance as ∆m = 1 and ∆t = 2,
and let the weight function be the unit weight function wI . Thus, an instance of the
MFM is constructed.
Within the mass window of an edge ek = (vi, vj), there are exactly two time
windows (corresponding to vi and vj) that have the construction of Figure 7.3(a) and
Figure 7.3(b), respectively. All other (n− 2) time windows have the construction of
Figure 7.3(c). Therefore, there are exactly 6n white features and 6n black features
in the mass window. Consequently, the number of matches within a mass window is
upper-bounded by 6n.
If an identity time alignment function, f(t) = t, is used, the isolated black features
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Figure 7.1: An Illustration of features plotting on a mass-time grid. Each horizontal
line on the plane corresponds to one time unit in the LC-MS experiment, and each
vertical line corresponds to a mass unit.
Figure 7.2: An illustration of the construction that highlights edge ek and vertex vi.
95
CHAPTER 7. MAXIMUM PEPTIDE FEATURE MATCHING
for vi and vj will not be matched. To match the isolated black feature of vi in
Figure 7.3(a), one can set either set f(6i− 1) = 6i or f(6i− 1) = 6i− 2. Suppose the
function f(6i − 1) = 6i is selected. Then the black feature at time (6i − 1) can be
matched to the white feature at time (6i+ 2), because |6i+ 2− f(6i− 1)| = 2 ≤ ∆t.
Meanwhile, this will force the black feature at time (6i+2) to match the white feature
at (6i+ 4), since the white feature at (6i+ 2) has already been matched by f(6i− 1).
This shifted matching propagates upward, as shown in Figure 7.4, until the isolated
white feature at time T is matched. Similarly, if we let f(6i − 1) = 6i − 2 and
match the isolated black feature of vertex i downward, then the shifted matching will
propagate downward to use the white feature at time 1.
For each mass window for an edge e = (vi, vj), there are only two isolated white
features at time 1 and T , respectively. Therefore, the two isolated black features for
vi and vj have to be matched to the opposite directions in order to be both matched,
in which case the number of matches is exactly 6n for this mass window. However, if
the two isolated black features are not matched to the opposite directions, only one
of the two isolated white features can be used and the maximum number of matches
is at most 6n− 1.
Thus, if the max-cut has a solution V = V1 ∪ V2 that cuts K edges, we can
construct a time alignment function f , such that
f(t) =

t+ 1, if t = 6i− 1 and vi ∈ V1,
t− 1, if t = 6i− 1 and vi ∈ V2,
t, otherwise.
(7.3)
From the above discussion one can easily verify that each time window for a cut edge
provides 6n matches and each of other time windows provides 6n − 1 matches. The
MFM instance has a total weight of (6n− 1)m+K.
On the other hand, suppose the MFM instance has (6n− 1)m+K matches, and
f is the time alignment function. Let V1 = {vi|f(6i− 1) ≥ 6i} and V2 = V \ V1. We
get a solution for the max-cut instance. Because the number of matches in each mass
window is upper bounded by 6n, and there are 6(n− 1)m + K matches in total, we
know that at least K mass windows provide 6n matches in each. For each of these K
mass windows that corresponds to ek = (vi, vj), from the above discussion we know
that the two isolated black features for vi and vj have to be matched to two opposite
directions. In another word, the edge ek is cut by separating its two vertices into V1
and V2. Consequently, the constructed solution will cut at least K edges.
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(a) (b) (c)
Figure 7.3: Illustrations of three cases to construct the grayed-out region: (a) ek =
(vi, vj) and i < j; (b) ek = (vj, vi) and i > j; and (c) vi is not adjacent to ek.
Figure 7.4: A shifted matching propagates upward when f(6i− 1) = 6i.
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Thus, we have shown that max-cut ≤P MFM, which proves the MFM problem is
NP -hard. 
7.3 A Practical Algorithm for Maximum Feature
Matching
In this section we develop a practical algorithm for MFM. This is achieved by studying
a slightly modified MFM problem. Instead of requiring the matching to be a bijective
mapping, the modified problem only requires the matching to be a surjective mapping.
More specifically, a surjective matchingM∗ is a subset of {(p, p′)|p ∈ S, p′ ∈ S ′}, where
p ∈ S appears at most once and p′ ∈ S ′ can appear multiple times. Given a time
alignment function f and a weight function w, the weight of the surjective matching
M∗ can be defined in the same way as in the MFM problem:
w(M∗) =
∑
(p,p′)∈M∗
w (|m(p′)−m(p)|, |t(p′)− f(t(p))|) . (7.4)
Given two samples and a weight function w, the maximum surjective feature
matching problem (SFM) is to compute a time alignment function and a surjective
matching M∗, such that w(M∗) is maximized. We next present a polynomial time
algorithm for the SFM problem.
For a sample S and a time i, let Si = {p ∈ S|t(p) = i} be the subset of features
at time i. Let S≤i = {p ∈ S|t(p) ≤ i} be the subset of features with time at most i.
Let di,j be the maximum weight of a surjective matching between Si and S
′ that
can be achieved by a time alignment function satisfying f(i) = j. Since the time of
all features in Si is equal to i and f(i) = j, di,j can be easily computed by finding the
best matching of each p ∈ Si separately.
Let Di,j be the maximum weight of a surjective matching between S≤i and S ′
that can be achieved by a time alignment function satisfying f(i) ≤ j. If f(i) < j,
it is clear that Di,j = Di,j−1. If f(i) = j, the maximum surjective matching includes
the maximum surjective matching from S≤i−1 to S ′, and the maximum surjective
matching from Si to S
′. Therefore, Di,j = Di−1,j + di,j. Combining the two cases,
we know that Di,j = max{Di,j−1, Di−1,j + di,j}. With this recurrence relation, the
SFM problem can be solved using a dynamic programming algorithm (Algorithm 3).
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The optimal time alignment function f , as well as the surjective matching, can be
computed by a standard backtracking.
Algorithm 3 Algorithm to solve the SFM problem.
1: for i← 0 to T do
2: for j ← 1 to T do
3: Compute di,j
4: for i← 0 to T do
5: Di,0 ← 0, D0,i ← 0
6: for i← 1 to T do
7: for j ← 1 to T do
8: Di,j = max{Di,j−1, Di−1,j + di,j}
9: Output DT,T as the maximum weight of the surjective matching.
Tracing back from DT,T , all (i, j) pairs on the optimal path form the optimal time
alignment function f .
Theorem 7.3.1 The SFM problem can be solved in O(T 2 + T × |S| × |S ′|) time by
Algorithm 3.
Proof. The correctness of the algorithm is shown by the above discussion and the
proof of the time complexity is as following. The computation of each di,j in line 3
takes at most O (|Si| × |S ′|) time. Therefore, the whole loop at lines 1 to 3 takes time
O
(∑
1≤i,j≤T |Si| × |S ′|
)
= O (T × |S| × |S ′|). After di,j is computed and stored in
memory, each execution of line 6 takes constant time. Thus, the loops from line 6 to
line 8 take O(|T |2) time. 
The computation of all di,j is the most time-consuming part of Algorithm 3 and
takes O(T × |S| × |S ′|). However, it is possible to speed up this part if the weight
function w satisfies some properties.
Corollary 7.3.2 If the unit weight function wI is used, SFM can be solved in time
O
(
T 2 + T × |S|+ |S| × |S ′|) .
Proof. We only need to show that di,j can be computed with time O(T × |S| +
|S| × |S ′|) for all 1 ≤ i ≤ T and 1 ≤ j ≤ T . For each p ∈ S, let Jp = {j|∃p′ ∈
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Algorithm 4 Algorithm to compute Jp.
1: Jp ← ∅
2: for p′ ∈ S ′ do
3: if |m(p′)−m(p)| ≤ ∆m then
4: Jp = Jp ∪ [t(p′)−∆t, t(p′) + ∆t]
S ′ such that |m(p′) − m(p)| ≤ ∆m and |t(p′) − j| ≤ ∆t}. Jp can be computed by
Algorithm 4.
In Algorithm 4 we need a data structure to store Jp ⊂ [1, T ], which is the union
of retention time intervals with the same length 2∆t + 1. Let A be a boolean array
of length T that is used to store if A[j] is the start position of one of the intervals.
This structure can help to make the adding of a new interval take only O(1) time.
To enumerate all j ∈ Jp takes at most O(T ) time, we propose Algorithm 5:
Algorithm 5 Algorithm to enumerate Jp.
1: counter ← 0
2: for j ← 1 to T do
3: if A[j] is true then
4: counter ← 2∆t + 1
5: if counter > 0 then
6: Output j
7: counter ← counter − 1
Thus, the complexity of the Algorithm 4 is O(|S ′|). After Jp is obtained, di,j can
be calculated by di,j = |{p ∈ Si|j ∈ Jp}|. The calculation of di,j for all 1 ≤ i ≤ T and
1 ≤ j ≤ T can be carried out more efficiently with Algorithm 6. Since Algorithm 4
takes O(|S ′|) time for each p ∈ S, the accumulated time cost for line 2 is O (|S| × |S ′|).
Since |Jp| ≤ T , line 7 is repeated at most O(
∑T
i=1 |Si| × T ) = O (|S| × T ) times.
Therefore, the total time complexity for Algorithm 6 is O (T × |S|+ |S| × |S ′|). 
Additionally, in Algorithm 4, if S ′ is sorted by mass values, we can retrieve all p′
such that |m(p′)−m(p)| ≤ ∆m by a binary search, without enumerating all p′ ∈ S ′.
Because usually ∆m  T and |S ′| > T , this trick can significantly speed up in
practice.
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Algorithm 6 Algorithm to calculate di,j.
1: for i← 1 to T do
2: Calculate Jp for each p ∈ Si with Algorithm 4;
3: for j ← 1 to T do
4: di,j ← 0
5: for p ∈ Si do
6: for j ∈ Jp do
7: di,j = di,j + 1
Lemma 7.3.3 Suppose two instances of SFM and MFM share the same input, the
weight of the maximum feature matching (MFM) is less than or equal to the weight
of the maximum surjective feature matching (SFM).
Proof. A bijective mapping is also surjective. This indicates that a solution to MFM
is also a solution to SFM. 
There exists a straightforward way to convert the optimal solution for SFM to
a suboptimal solution for MFM. Let M∗ ⊂ {(p, p′)|p ∈ S, p′ ∈ S ′} be a solution to
SFM, such a conversion can be done by selecting only one pair of features from M∗ for
every p′ ∈ S ′. Furthermore, Algorithm 7 can generate a better suboptimal solution
for MFM based on the optimal solution to SFM.
Algorithm 7 Algorithm SMFM to provide a suboptimal solution for the MFM prob-
lem.
1: Compute an optimal solution for SFM using Algorithm 3;
2: Let f be the optimal time alignment function;
3: Let wu be the optimal weight of SFM;
4: for p ∈ S do
5: for p′ ∈ S ′ do
6: w˜(p, p′) = w (|m(p′)−m(p)|, |t(p′)− f(t(p))|)
7: Treat w˜(p, p′) as the edge weight in a complete bipartite graph S×S ′, and compute
a maximum bipartite matching;
8: Let wl be the weight of the maximum bipartite matching;
9: Output the maximum bipartite matching as the suboptimal solution to MFM, wu
as the upper bound of the optimal weight of MFM, and wl as the lower bound.
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Theorem 7.3.4 Algorithm SMFM computes a suboptimal solution for the MFM
problem, and determines an upper-bound and a lower-bound of the optimal weight.
Proof. The theorem is an immediate consequence of Lemma 7.3.3. 
Since MFM is NP -hard, there is no polynomial time algorithm for finding the
optimal solution unless P=NP. Therefore, Algorithm SMFM can be used in practice
to find a suboptimal solution.
7.4 Variations of the Maximum Feature Matching
Problem
In this section we examine two variations of the MFM problem. A more accurate
weight function is introduced in the first variation, and a gap penalty for the time
alignment is added in the second variation. The gap penalty can help make the time
alignment function smoother.
7.4.1 Weight Function
The unit weight function wI is conceptually simple and the mass and time error
thresholds ∆m and ∆t can be easily determined by the technician who operates the
instrument according to experience. However, it is sometimes desirable to use a
continuous weight function to give different weights to different time errors.
It has been shown that in real data the random retention time error after the
time alignment satisfies a normal distribution [43]. Let i = t(p
′
i) − f(t(pi)) be the
random time error of a pair of matched features (pi, p
′
i) after the time alignment and
Pr(i) =
1
σ
√
2pi
e−
1
2(
i
σ )
2
be the probability distribution of i. Assume the random error
of different features are independent to each other, then the probability of all the
errors in the matching is
∏n
i=1
1
σ
√
2pi
e−
1
2(
i
σ )
2
. By taking the logarithm, it is easy to see
that maximizing the above probability is equivalent to minimizing
∑n
i=1 i
2. Because
the weight function needs to be nonnegative, we define the following weight function
w2:
w2 (δm, δt) =
{
∆2t − δ2t , if δm ≤ ∆m and δt ≤ ∆t,
0, otherwise.
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7.4.2 Gap Penalty
In the definition of the MFM and SFM problems, the time alignment function f is
only restricted to be a monotonically increasing function. However, it is sometimes
beneficial to require some smoothness of f since fewer data points are required to fit
a smooth function.
Let [li, ri] (i = 1, . . . , k) be the maximal time intervals such that ri − li > 1 and
f(t) remains a constant in each interval. These are called the type-I gaps. The gap
length for [li, ri] is ri− li. Let [l′i, r′i] (i = 1, . . . , k′) be the maximal time intervals such
that there is no t satisfying f(t) ∈ [l′i, r′i]. These are called the type-II gaps. The gap
length for [l′i, r
′
i] is l
′
i − r′i + 1. By requiring f to be smooth, we essentially want to
penalize these two types of gaps with a gap penalty function g(k) > 0 for a length-k
gap.
This is analogous to the gaps in the pair-wise sequence alignment. The major
difference is that here we prefer many smaller gaps over a few large gaps. Therefore,
in contrast to using a concave gap penalty function in a sequence alignment, a convex
gap penalty function, such as g(k) = k2, is chosen, and the total gap penalty of the
time alignment function f is defined as
g(f) =
k∑
i=1
g(ri − li) +
k′∑
i=1
g(r′i − l′i + 1). (7.5)
The gapped-MFM problem is to find a bijective feature matching M and a time
alignment f to maximize score(M, f) = w(M) − g(f). Similarly, the gapped-SFM
problem is to find a surjective feature matching M∗ and a time alignment f to max-
imize score(M∗, f) = w(M∗)− g(f).
We design a dynamic programming algorithm for the gapped-SFM problem. Let
K > 0 be the maximum allowed gap length. Let Si, S≤i and di,j be as defined in
Section 7.3. Let Ni,j be the maximum score achieved by features in S≤i and a time
alignment function satisfying f(i) = j and f(i − 1) < j. Let Mi,j be the maximum
score achieved by features in S≤i and a time alignment function satisfying f(i) = j.
From the definition of Ni,j, we know that [f(i−1)+1, f(i)−1] is a probable type-II
gap. Let k = f(i)− f(i− 1)− 1 be the gap length. Then, f(i− 1) = f(i)− k − 1 =
j − k − 1, and therefore
Ni,j = max
0≤k≤K
{Mi−1,j−k−1 + di,j − g(k)} (7.6)
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To compute Mi,j, assume that i − k is the least number such that f(i − k) = j.
Then [i− k, i] is a probable type-I gap, and therefore,
Mi,j = max
0≤k≤K
{Ni−k,j +
i∑
l=i−k+1
dl,j − g(k)} (7.7)
From Eq. (7.6) and Eq. (7.7), it is straightforward to develop a dynamic program-
ming algorithm (Algorithm 8) to compute Ni,j and Mi,j simultaneously. The time
complexity will be O(T 2K) plus the time needed by computing di,j. Therefore, for a
general weight function w, the time complexity is O(T 2K + T × |S| × |S ′|).
Algorithm 8 Algorithm SFM-g to solve the gapped-SFM problem.
1: for i← 0 to T do
2: for j ← 1 to T do
3: Compute di,j
4: for k ← 0 to T do
5: N0,k ← −g(k)
6: Mk,0 ← −g(k)
7: for i← 0 to T do
8: for j ← 1 to T do
9: Ni,j = max0≤k≤K{Mi−1,j−k−1 + di,j − g(k)}
10: Mi,j = max0≤k≤K{Ni−k,j +
∑i
l=i−k+1 di,j − g(k)}
11: Output NT,T as the maximum weight of the surjective matching.
Since MFM isNP -hard, gapped-MFM with a general gap penalty is alsoNP -hard.
Algorithm SMFM in Section 7.3 can be slightly modified to Algorithm SMFM-g to
provide a suboptimal solution for gapped-MFM and an upper bound to the optimal
score. The only required modification is to use Algorithm SFM-g in line 1 of the
algorithm, instead of using the algorithm for SFM (Algorithm 3).
7.5 Experimental Results
The performance of our algorithms was compared with three other state-of-the-art
software tools, msInspect [13], MZmine2 [121], and MultiAlign [84] by using real LC-
MS data sets. Our algorithms include: (1) Algorithm SMFM with the weight function
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w2, and (2) the algorithm with weight function w2 and a gap penalty g(k) = 10k
2,
as described in Section 7.4. For the rest of the section, the first algorithm will be
denoted by SMFM, and the second algorithm will be denoted by SMFM-g.
Five LC-MS data sets, which were produced from the yeast proteome by three
different labs, were chosen for the performance evaluation. All of these data sets were
published in previous research [7, 142, 110]:
iPRG2011: The data was from the “Proteome Informatics Research Group
study” in 2011 [7]. Saccharomyces cerevisiae lysate is digested by Lys-C followed by
strong cation exchange chromatography (SCX) fraction. 10 fractions were selected
from 15 fractions. Each fraction is was analyzed by LC-MS/MS with a Thermo LTQ-
Orbitrap XL. The LC separation is done in a flow rate of 200nl/min using a 75µm
× 10 cm column packed with 3um particle size Reprosil C18AQ (Solvent A: 0.1%
formic acid, Solvent B: 90% acetonitrile/0.1% formic acid, Gradient: load at 3%B,
elute with 5-35%B in 90 min, elute with 35-90%B in 10 min; wash at 90%B for 9 min.
10-20 sec chromatographic peak widths). Orbitrap was used to collect high resolution
MS spectra. 8 most abundant precursor were fragmented in data dependent mode to
produce MS/MS. There are 22,087 MS scan and 103,185 MS/MS scan for all these
10 fractions. In our experiment the LC-MS data of fraction 1 was picked from the 10
published fractions for software performance evaluation.
Coon: This data was produced from two biological replicates in the Coon research
group [142]. A whole cell yeast lysate was digested using the protease endo-LysC and
was separated into 12 fractions by SCX fraction. Each fraction is loaded in online
nanoflow reversed-phase liquid chromatography coupled to MS/MS (nLC-MS/MS),
using a forty minute linear gradient of 1.4% to 49% acetonitrile in 0.2% formic acid
with data-dependent precursor selection. Eluting peptide cation populations were
analyzed using the Orbitrap for MS and QLT for MS/MS product ion spectra. We
chose two LC-MS data sets from fraction 3 of biological replicate 1 (Coon1.F3) and
fraction 4 of biological replicate 2 (Coon2.F4) in our experiment. Coon2.F4 shared
the most number of peptides with the iPRG data set, and Coon1.F3 was the fraction
in replicate 1 that shared the most number of peptides with Coon2.F4.
Mann: The data was from the single-shot LC-MS/MS system in Mann Lab [110]
measured six yeast cell lysate separately. Each is digested by LysC digestion using the
FASP method. Peptides were loaded on a 50 cm column with 75-µm inner diameter,
packed in-house with 1.8-µm C18 particles (Dr. Maisch GmbH, Germany). Reversed
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Table 7.1: The number of features in different samples.
iPRG Coon1.F3 Coon2.F4 Mann.1 Mann.2
Feature
11,430 5,879 5,320 66,479 68,128
Number
phase chromatography was performed using the Thermo EASY-nLC 1000 with a
binary buffer system consisting of 0.5% acetic acid (buffer A) and 80% acetonitrile
in 0.5% acetic acid (buffer B). The peptides were separated by a linear gradient
of buffer B up to 40% in 240 min for a 4h gradient run with a flow rate of 250
nl/min in the EASY-nLC 1000 system. Eluting peptides were analyzed on the bench-
top quadrupole Orbitrap mass spectrometer(Q Exactive) and the top 10 abundant
peptide ions in a survey scan were fragmented using HCD. We chose the first two
biological replicates (Mann.1 and Mann.2) for the software performance evaluation
in our experiment.
The names of the data sets and the number of features detected by msInspect
in each of them are listed in Table 7.1. These five data sets are aligned with one
another under different settings. More specifically, the alignments Coon1.F3 vs.
Coon2.F4 and Mann.1 vs. Mann.2 are data sets from the same lab on the same
instrument in the same experiment. These reflect the easiest test cases since the
LC conditions do not vary too much. The alignments iPRG vs. Coon2.F4 and
Coon2.F4 vs. Mann.1 reflect the most challenging test cases, since the aligned
data sets were from different labs and the LC conditions across different labs present
the largest possible variations. However, since they were all produced from the yeast
proteome, there should be a significant number of peptides shared by the data sets.
Therefore a robust feature matching algorithm should still be able to match these
common peptides’ features, despite the existence of large retention time distortion
and noises.
For each data set, the MS/MS spectra were used to identify peptides with the
PEAKS [166]. The yeast protein database was searched with following search param-
eters:
• parent mass error tolerance = 20 ppm (part-per-million);
• fragment mass error tolerance = 0.5 Da;
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• fixed PTM: carbamidomethylation on Cys (+57.02);
• variable PTMs: deamidation on Asn and Gln (+0.98), methyl ester on Lys
(+14.02), and oxidation on Met (+15.99).
The peptides identified with FDR ≤ 1% and matched by only one feature in the
LC-MS data were selected as a control set. This control set was a subset of “true”
peptide feature matches between different data sets and used to evaluate different
software’s performance.
Each of the compared software tools, SMFM, SMFM-g, msInspect, MZmine2, and
MultiAlign, was used to produce the pairwise time alignment for iPRG vs. Coon2.F4,
Coon2.F4 vs. Mann.1, Coon1.F3 vs. Coon2.F4, and Mann.1 vs. Mann.2, respectively.
The m/z and retention time error tolerance of each software were set to be the same
whenever possible. More specifically, ∆t was set to be five minutes for the samples
from different labs (iPRG vs. Coon2.F4 and Coon2.F4 vs. Mann.1) and two minutes
for the ones from the same lab (Coon1.F3 vs. Coo2.F4 and Mann.1 vs. Mann.2).
Other unique parameters of a software tool were set separately to achieve its own
best performance:
1. SMFM: ∆m = 15 ppm (part-per-million).
2. SMFM-g: ∆m = 15 ppm, gap penalty g(k) = 10k
2.
3. msInspect: spline mode, mass error tolerance = 15ppm.
4. MZmine2: RANSAC algorithm mode, m/z tolerance = 10 ppm 1, retention time
tolerance (before correction) = 50 minutes, number of RANSAN iterations =
auto, minimal number of points = 20%, threshold value = 3, and same charge
state was required.
5. MultiAlign: mass tolerance = 15 ppm, and hybrid recalibration was selected.
The peptide features detected by msInspect from the LC-MS raw data were ex-
ported as the input of SMFM, SMFM-g, and msInspect. MultiAlign and MZmine2 do
not accept features detected by msInspect. Therefore, MultiAlign used the features
detected by DeconTools [138] which was the preferred feature detection method of
MultiAlign. MZmine2 used its own feature detection result.
1Error tolerance 15ppm crashed the software
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Table 7.2: The comparison of average aligned time errors (in seconds) and the per-
centages of correctly aligned feature pairs on true peptide features.
SMFM SMFM-g msInspect MZmine2 MultiAlign Polynomial-4
iPRG- 36.6 35.2 114.8 55.0 126.0 30.3
Coon2.F4 (100%) (100%) (87%) (99%) (92%) (100%)
Coon2.F4- 63.9 62.1 97.1 65.7 78.7 66.2
Mann.1 (82%) (82%) (71%) (80%) (73%) (79%)
Coon1.F3- 8.4 7.4 11.3 21.8 27.8 8.2
Coon2.F4 (100%) (100%) (96%) (94%) (89%) (100%)
Mann.1- 14.5 13.0
- -
16.4 15.7
Mann.2 (90%) (87%) (81%) (86%)
The performance of each method was measured quantitatively with the average
aligned time error of the true feature pairs. More specifically, for each pair of features
p = (m(p), t(p)) and p′ = (m(p′), t(p′)) that were from the two compared samples and
shared the same peptide, the aligned time error was calculated as |f(t(p)) − t(p′)|,
where f(·) was the retention time alignment function calculated by each software tool.
The average aligned time error and the percentage of correctly aligned “true” feature
pairs of each software applying on each pair of data sets are provided in Table 7.2. A
feature pair is considered as correctly aligned if their aligned retention time difference
is below the specified threshold in each experiment.
Although the five above mentioned software tools did not use the peptide iden-
tification deliberately, just for curiosity, the average aligned time errors obtained by
a simple method (Polynomial-4) that used the peptide identification were also added
in Table 7.2. By using the true feature pairs derived from the peptide identification,
the Polynomial-4 method fitted a fourth degree polynomial as the time alignment
function.2 This was an unfair comparison because Polynomial-4 used additional infor-
mation. Nevertheless, Table 7.2 showed that our new methods SMFM and SMFM-g
also compared well to this polynomial fitting. This indicated that the time alignment
function could not be fit accurately by a low degree polynomial, and further justified
the use of a monotonically increasing function instead of any specific simple function
in our SMFM model. For the alignment of Mann.1 vs. Mann.2, both msInspect and
2The second and third degree were also tried but the results were not as good as the fourth
degree.
108
7.6. DISCUSSION
MZmine2 failed (msInspect crashed and MZmine2 returned no result). We suspected
that it was due to the large data size of Mann’s data sets (see Table 7.1). Our new
algorithms (SMFM and SMFM-g) finished successfully in less than one minute with
560 MB of memory usage.
Figure 7.5 illustrates the relative performance of the six compared methods vi-
sually. The resulting time alignment from each software was plotted together with
the “true” peptide feature pairs (represented by blue circles). Retention time of both
samples were scaled to 3,600 seconds in the figure. All the possible feature pairs that
had a mass difference less than 15 ppm were also plotted as gray crosses. Thus, intu-
itively, the software tools were using these gray crosses to compute a time alignment
function. A better software tool can generate an alignment function that fits the
trend of blue circles.
Similar figures for the alignments between biological replicates, Coon1.F3 vs.
Coon2.F4 and Mann.1 vs. Mann.2, were plotted in Figure 7.6. The time alignment
functions on these data sets were almost linear functions.
7.6 Discussion
The maximum feature matching problem (MFM) is formulated to match the peptide
features in label-free peptide quantification. To our knowledge this is the first combi-
natorial model for the problem. We show that the problem is NP -hard and provide
practical algorithms that guarantee the performance for each instance. Experiments
on real data demonstrate that our algorithms have better performances comparing to
other software in the literature.
While recognizing the requirement and contribution of ad hoc software tools in
bioinformatics research, we advocate that, whenever possible, a bioinformatics prob-
lem should have a clear combinatorial definition. This traditional practice in algorith-
mic research can help reduce the risk of overfitting the training data in the process of
seeking for a better algorithm. It also helps predict the performance of an algorithm
before implementing and running the software.
A feature p is defined by a pair (m(p), t(p)) in our study. However, more informa-
tion about a peptide feature retrieved from the LC-MS data can be added by replac-
ing m(p) with an information vector. Meanwhile, in the wight function w(δm, δt), δm
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(a) iPRG vs. Coon2.F4
(b) Coon1.F3 vs. Mann.1
Figure 7.5: Comparison of the feature matching software tools on data sets from
different labs: iPRG vs. Coon2.F4 (a) and Coon1.F3 vs. Mann.1 (b). The x-axis
denotes the retention time in the first sample and the y-axis denotes the retention
time in the second sample. A blue circle, which stands for a feature pair matched
according to peptide identification, is considered as the ground truth. A gray cross
represents a possible feature pair matched purely by the precursor mass. The curves
are produced by the compared algorithms without knowing the blue circles.
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(a) Coon1.F3 vs. Coon2.F4
(b) Mann.1 vs. Mann.2
Figure 7.6: Comparison of the feature matching software tools on data sets from the
same lab: Coon1.F3 vs. Coon2.F4 (a) and Mann.1 vs. Mann.2 (b). As msInspect
and MZmine2 failed to align the data set Mann.1 and Mann.2, only results of SMFM,
SMFM-g, MultiAlign, and Polynomial-4 are shown in (b).
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needs to be replaced by the distance of the two vectors of the compared features. For
example, the intensity distribution over the isotopic peaks and over the retention time
can be used to measure the similarity (or matching quality) of two matched features.
The NP -hardness and algorithms remain the same in such case.
Researchers develop bioinformatics software to help find “real” biological solutions
from their experimental data. However, as the real solution is unknown before using
the software, the optimization goal is at most an approximation to the properties
of the real solution, instead of the real solution itself. We have demonstrated that
a clear definition of such an optimization goal has converted a biological problem
to a pure combinatorial problem that is readily for algorithmic research. Meanwhile,
performances of the algorithms that proposed for this combinatorial problem compare
favorably to the state-of-the-art ad hoc software packages.
In fact, a clear definition of the optimization goal is helpful even in ad hoc solutions.
For example, previous research has suggested alternately finding a time alignment and
a set of matching features by using each other as the input. It is not guaranteed that
such iteration can converge or improve the result. However, if the optimization goal is
definite, the iteration can be evaluated after each loop and terminated when a certain
requirement is achieved.
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Chapter 8
Conclusions and Future Work
8.1 Conclusions
In this dissertation, MS/MS-based computational proteomics is explored on both
protein identification and quantification. The major content focuses on peptide iden-
tification, especially the modified peptide identification.
Protein identification is to interpret the spectral data and thus retrieve the protein
and PTM information. A large number of software packages, using database search or
de novo sequencing approaches, have been developed and undoubtedly accelerated the
progress of proteomics studies. However, with the rapid development in experimental
strategies and the mass spectrometry instruments, people are not satisfied by current
status in computational proteomics. On one hand, the accuracy and the resolution
of the instruments are kept getting better, and it is more flexible to choose different
techniques in an experiment. Thus, it is theoretically possible to improve the accuracy
of de novo sequencing and make it become a more practical approach. On the other
hand, only identifying proteins in a given sample is still far away from the goals of
proteomics. A thorough study on proteins and their PTMs demands sophisticated,
and specifically designed computational approaches. Thus, this dissertation provides
algorithmic solutions to fulfil these urgent requirements.
MS/MS instruments that implement multiple fragmentation modules can generate
different types of mass spectral data for the same sample. This inspired us to design
a novel scoring scheme, ADEPTS, to improve the performance of de novo sequencing
in Chapter 3. Features from two types of spectra are considered simultaneously in
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this scoring scheme. The comparison between ADEPTS and other software tools,
including PEAKS on CID and ETD data separately, PepNovo on CID data, and
CompNovo on CID/ETD spectrum-pairs, shows that ADEPTS performs better on
both correctly identified peptides and residues.
Novel proteins can be sequenced using de novo sequencing approaches, but identi-
fying PTMs of these proteins is a nontrivial challenge. Conventionally, users need to
specify many PTMs that possibly exist in a sample to a de novo sequencing software
tool. It increases the running time and degrades the result accuracy significantly.
Our novel dynamic programming algorithm, DeNovoPTM, is proposed in Chapter 4
to solve this problem by limiting the number of PTM occurrences per peptide. Ex-
periments show that DeNovoPTM outperforms other two state-of-the-art de novo
sequencing software, PEAKS and PepNovo, on modified peptide identification when
many PTMs types are considered.
Database search has been regarded as a reliable protein identification approach.
However, conventional database search tools cannot provide a PTM search efficiently
and accurately when a large number of PTMs are specified. We propose PeaksPTM
in Chapter 5 as an improved database search approach to enable the unrestricted
PTM identification. Different from conventional database search tools, PeaksPTM
does not require users to specify PTMs in advance; instead, all the PTMs recorded
in the Unimod database are considered in the search by default. A modified target-
decoy strategy is also applied to control false positives. PeaksPTM makes it possible
to unrestrictedly and confidently identify the general PTMs existing in a complex
biological sample. Experiments show that PeaksPTM achieves a stronger performance
than competitive tools for unrestricted identification of PTMs.
Glycosylation is one of the most frequently observed PTMs and plays important
roles in many disease processes, such as cancer. Identification of glycopeptides and
glycans is essential to better understand the functions and bioactivities of glycopro-
teins. The progress of this study is mainly hindered by the lack of algorithms for
intact glycopeptide characterization. We propose GlycoMaster DB in Chapter 6 to
fulfil this urgent requirement onN -linked glycopeptides. GlycoMaster DB can analyze
on a large-scale MS/MS dataset obtained from a biological sample with glycoproteins
being either enriched or not, and from either HCD/ETD or HCD-only fragmentation.
It enables the simultaneous identification of glycopeptide sequences and N -linked gly-
can composition from a user-specified protein database and a pre-configured N -linked
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glycan database, respectively. Testing on four datasets demonstrates the promising
performance of the software.
Protein quantification provides the information of protein quantity changes and
assists in discoveries of important biomarkers in disease studies. Matching the pep-
tide features extracted from different datasets is a crucial step to calculate the protein
abundance ratios. Heuristic approaches have been proposed in previous research but
none of them has yet claimed a clear optimization goal. In Chapter 7, a combina-
torial problem, maximum peptide feature matching, is formulated and proven to be
NP -hard. Practical algorithms are presented to solve the problem approximately in
polynomial time and can help determine an upper-bound and a lower-bound of the
optimal solution. The performances of our algorithms also compare favorably to other
existing methods.
8.2 Future Work
Our future work will focus on providing algorithmic solutions for computational
challenges encountered in mass spectrometry-based proteomics, especially glycopro-
teomics.
In the dissertation we introduce two approaches to improve the performance of
de novo sequencing, and a new approach can be proposed for better identification of
PTMs. When the number of PTM types increases, the accuracy of DeNovoPTM’s
result does not degrade too much in contrast to the conventional algorithms, but it
is still not confident enough for practical use. More information is required to pre-
cisely identify the PTMs, which inspires the possible application of the DeNovoPTM
algorithm on spectral data obtained from multiple fragmentation methods. Different
fragmentation patterns can confirm each other on the discrimination between true
and spurious fragmentation sites. It can be foreseeable that this combination can
increase the confidence of PTMs identified from de novo sequencing.
Glycoprotein characterization is an urgent task in the emerging computational gly-
coproteomics. Several open problems need to be addressed in the near future. The
first challenge is to refine the scoring scheme for the combination of spectra obtained
from two types of fragmentation methods. It has been proven that two commonly
used fragmentation methods (HCD and ETD) can fragment a glycopeptide with sig-
nificantly different mechanisms. Therefore, utilization of both types of spectra can
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simultaneously identify glycopeptides and glycan composition with higher confidence.
Our preliminary experiments have shown that a straightforward scoring scheme can
improve the identification from HCD/ETD spectral data. However, a sophisticated
scoring model considering multiple types of spectra, as well as an improved experi-
mental strategy, is strongly required for more confident characterization.
The second challenge is to construct and maintain a spectrum library of glycopep-
tides for MS/MS data analysis. This concept is similar to spectral library search:
searching a given spectrum in a spectral library constituted by previously identified
spectra, and using the best matched one to interpret the given spectrum. Such a
spectral library is currently not available because of the lack of automated glycopep-
tide identification tools, and our GlycoMaster DB can fulfill the requirement. This
research area is in its infancy and the library has the significant potential to accelerate
the progress of the emerging glycoproteomics research.
The third challenge is to interpret the spectral data generated by O-linked gly-
coproteins. MS/MS spectra produced by O-linked glycopeptides are different from
the ones by N -linked glycopeptides, and thus algorithms designed for N -linked gly-
copeptide characterization need to be cautiously revised. A large-scale analysis of
glycoproteome in a biological sample demands a universal framework that character-
izes both N -linked and O-linked glycopeptides, instead of using separated approaches.
Furthermore, an effective statistical model is also required to control false positives.
In addition, the determination of glycan structures, rather than glycan compo-
sition, is another non-trivial extension of the glycopeptide characterization problem
and demands experimental and computational solutions.
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